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INTRODUCTION 
 
1.1 Drug delivery system 
              The treatment of acute diseases or chronic illness was achieved by 
delivery of drugs to  patients from many years. These drug delivery systems 
include tablets, injectables, capsules, suspensions, creams, ointments, liquids and 
aerosols. Nowadays these  drug delivery systems are widely used. The term drug 
delivery system can be defined as techniques which are used for getting  
therapeutic agents inside the human body.
1 
An ideal drug delivery system must contain two pre requisites.
 2
 
1. It deliver the drug at a rate dictated by the needs of the body over the 
period of treatment. 
2. Spatial targeting to specific sites. 
              These prerequisites provide a need for modified drug release 
technologies, which can improves the therapeutic efficacy and safety of a drug by 
particular temporal and spatial placement in the body, thereby decreasing both  
size and number of doses required.
2 
1.2 Conventional drug delivery
 
              Conventional drug therapy requires periodic doses of therapeutic agents. 
These systems are formulated to produce maximum stability, activity and 
bioavailability. For many drugs, conventional methods of drug administration are 
effective, but some drugs are unstable or toxic and have narrow therapeutic 
window. Some drugs  possess solubility problems. In that cases, a method of 
continuous administration of drug is required to maintain fixed plasma levels. To 
overcome these problems, modified drug delivery systems were introduced.  
                These delivery systems have number of advantages over traditional 
systems such as improved efficiency, minimum toxicity and improved patient 
convenience. The main aim of modified drug delivery systems was to improve 
the effectiveness of drug therapies. 
3 
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1.3 Modified release dosage forms
 
  
                 Modified release dosage forms can be defined as one for which the 
release characteristics of time course and location are chosen to accomplish 
therapeutic or convenience objectives, which were not offered by conventional 
dosage forms. Mostly, modified release dosags forms were orally administered 
tablets and capsules. Several types of modified release dosage forms are 
available.
4
 
They include: 
      1.3.1 Delayed release dosage forms 
      1.3.2 Extended release dosage forms 
1.3.1 Delayed release dosage forms 
5 
                  Delayed-release dosage forms are the systems which were formulated 
to  release the active ingredient after predetermined time at a predetermine 
location.  E.g. when the dosage form reaches the small intestine (enteric-coated 
dosage forms) or the colon (colon-speciﬁc dosage forms). 
               These delayed release systems are used to protect the drug from 
degradation in the low pH acidic environment of the stomach or to protect the 
stomach from irritation by the drug. In these cases drug release should be delayed 
until the dosage form has reached the small intestine. Often polymers are used to 
achieve this aim. The dosage form (for example, a tablet or the granules before 
tableting) can be coated with a suitable polymer. The polymer dissolves as a 
function of pH, so when the dosage forms travels from the low-pH environment 
of the stomach to the higher-pH environment of the small intestine, the polymer 
coat dissolves and the drug can be released.  
The two types of delayed release systems are: 
1.3.1.a. Intestinal release systems 
1.3.1.b. Colonic release systems 
 
 3 
 
1.3.1.a. Intestinal release systems 
                   A drug may be enteric coated for intestinal release for several known 
reasons such as to prevent gastric irritation, prevent destabilization in gastric pH.
  
1.3.1.b. Colonic release systems 
                  Drugs are poorly absorbed through colon but may be delivered to such 
a site for two reasons. 
             a. Local action in the treatment of ulcerative colitis and 
     b. Systemic absorption of protein and peptide drugs  
The most commonly used pharmaceutical delayed release solid oral dosage forms 
today include tablets, capsules, granules and pellets. 
1.3.2 Extended release dosage forms 
6 
             
                   Extended release dosage forms were designed to achieve a prolonged 
therapeutic effect by     continuously releasing the drug over an extended period 
of time after administration of a single dose. Extended release dosage form 
allows at least two fold reduction in dosage frequency as compared to that drug 
presented in conventional dosage forms. 
Ex:  controlled release, sustained release.  
1.3.2.1. Controlled release drug delivery systems (CRDDS) 
                      More precisely, controlled delivery can be defined as 
1. Sustained drug action at a predetermined rate by maintaining a relatively 
constant, effective drug level in the body with concomitant minimization of 
undesirable side effects. 
2. Localized drug action by spatial placement of a controlled release system 
adjacent to or in the diseased tissue.  
3. Targeted drug action by using carriers or chemical derivatives to deliver drug 
to a particular target cell type.  
 4 
 
4. Provide a physiologically / therapeutically based drug release system. In 
other words, the amount and the rate of drug release are determined by the 
physiological/ therapeutic needs of the body.  
                    A controlled drug delivery system was usually designed to delivered 
the drug at particular rate. Safe and effective blood levels were  maintained for a 
period as long as the system continues to deliver the drug. This predetermined 
rate of drug release was based on the desired therapeutic concentration and the 
drug’s pharmacokinetics.   
1.3.2.2 Sustained release dosage forms 
                      It is defined as “any drug or dosage form modification that prolongs 
the therapeutic activity of the drug’’. Sustained release technologies can improve 
the therapeutic efficacy and safety of a drug by precise temporal and spatial 
placement in the body, thereby reducing both the size and number of doses 
required. Furthermore, the possibility of repeating successful drugs, coupled with 
the increasing expense in bringing new drug entities to market, has been 
instrumental in generating interest in sustained-release dosage forms.
 
 
                      The aim of oral sustained release dosage forms is to achieve a 
prolonged therapeutic effect by continuously releasing medicament over an 
extended period of time after administration of a single dose. Sustained release 
constitutes any dosage form that provides medication over an extended time 
period. In general, the Sustained release dosage form is to maintain therapeutic 
blood or tissue level of drug for a prolonged period usually accomplished by 
attempting slow first order fashion. In recent years sustained release dosage 
forms continuous to draw attention in the field of research for improved patient 
compliance and decreased incidence of adverse drug reaction.
 
                      The sustained release dosage form is defined as “any drug or 
dosage form modification that prolongs the therapeutic activity of the drug”. 
Once the maximum level is reached, the amount of drug in the body decrease 
slowly, so it will take longer to drop below the therapeutic range. 
 
                       The terms sustain or controlled drug release incorporates the 
element of prolongation of duration of drug action as well as the drug 
predictability and reproducibility in drug release kinetics. Polymeric sustained 
 5 
 
drug delivery systems offer numerous advantages when compared with 
conventional dosage forms, including improved efficacy, reduced toxicity, and 
improved patient compliance. 
 
                   Figure  1:  Plasma drug concentration –time profiles  
 
 
1.3.2.3Advantages of extended release dosage form
 7
 
 Improved patient compliance and convenience because of less 
frequent drug administration. 
 Reduction in fluctuations in steady state blood  levels and 
therefore, better control of disease condition and reduced 
intensity of local or systemic side effects. 
  For high potency drugs, due to better control of plasma levels 
increased safety margins can be achieved. 
 total amount of dose administered should be reduced through 
maximum utilization of drug. 
 Because of  improved therapy, shorter treatment periods, less 
frequent dosing and reduction in personnel time to dispense, 
administer and monitor patients  health care costs was reduced. 
 Sustained blood levels; the size and frequency of dosing are 
determined by the pharmacokinetic and pharmacodynamic 
 6 
 
property of drug. The use of extended release products may 
maintain therapeutic concentration over prolonged period. 
 Using of extended release products avoids the high initial   blood 
concentration, which  may causes  many  adverse effect,side 
effects like nausea, local irritation, haemodynamic changes etc 
are decreased.                                                                                                                                                                                                               
1.3.2.4 Disadvantages of extended release dosage form
 8
 
  Dose dumping causes toxicity 
 Increased cost. 
 Unpredictable and often poor in vitro- in vivo correlation. 
 Upon fast release of total drug (mechanical failure, chewing or 
masticating, alcohol intake) may causes  risks  like side effects or 
toxicity . 
 Epithelial lining (lodging of dosage forms) can be damaged due 
to local irritation. 
 Need for additional patient education and counseling. 
 Increased potential for first- pass clearance. 
1.3.2.5Ideal candidate for Extended/Controlled release drug delivery systems
9-11 
               The desired biopharmaceutical characteristics of drugs to be used for  
the     development    of per oral controlled release dosage forms are:  
 Molecular weight :  < 1000 mg 
 Solubility              :  0.1 mcg/ml 
           P
ka                                           
:  > 0.1% to 1 % at pH 1 to 7.8 
 Apparent partition coefficient   :  0.5 to 2.0 
 7 
 
 General absorbability :  From all GI segment 
 Stability :  Stable in GI environment 
Release should not be influenced by pH and   enzymes. 
Less protein binding 
 To evaluate whether a drug is viable candidate or not for the design of 
per oral CR formulation, one must consider the following pharmacokinetic 
parameters of the drug.  
    Elimination half-life               :      Preferably between 0.5& 8 hours 
    Total body clearance              :      Should not be dose dependent 
   Elimination – rate constant   :      Required for the design 
    Absolute bioavailability         :      Should be 75% or more 
    Absorption rate :     Must be greater than release rate 
Therapeutic concentration                            
              
 The lower the css and  smaller the vd the lesser was the amount 
required.                                                                           
Apparent volume of distribution (Vd) 
           The larger the apparent volume of distribution vd and Minimum 
Effective Concentration (MEC), the larger will be the dose size needed. The 
maximum dose to be incorporated into a per oral Controlled release (CR) 
formulations is about 500mg. The smaller the vd , the easier is incorporation of 
drug in to dosage form.  
               
 8 
 
1.3.2.6   Candidates unsuitable for Extended-Release Dosage Forms
12
   
 Short elimination biological half-life     
 E.g. Penicillin G,  Furosemide   
 Long elimination biological half life (>12hr)    
       E.g. Diazepam,  Phenytoin 
 Narrow therapeutic index        
 E.g.  Phenobarbital, Digitoxin. 
 Not effectively absorbed into the lower intestine.                                                 
E.g.  Riboflavin, Ferrous salts.  
 Large doses (>1g): 
  E.g,  Sulphonamides. 
 
 
1.3.2.7 Controlled Release Formulations
 13
 
  Types of Controlled Release Systems: 
Matrix type tablets  
 Hydrophobic and hydrophilic matrices. 
 Plastic matrices 
 Ion exchange resins 
 Co-precipitates and solid dispersions. 
 9 
 
Film-Coating Tablets 
 Diffusion-controlled membrane  
 Osmotic pumps 
 Floating Tablets  
 Swellable Tablets  
 Mucoadhesive Tablets 
 Complexation 
 Cyclodextrins 
 Pharmaceutical adhesives. 
Multiple-Unit Tablets 
II Capsules 
1.Hard gelatin capsules 
2.Soft elastic capsules 
3.Floating capsules 
III Micro granules/spheroids 
IV Beads 
V  Pellets 
 VI Emulsions 
VII Suspensions 
VIII Liposomes 
IX Microrparticles 
X Nano particles 
 10 
 
1.4  Pellets
14,15 
 
                     Pharmaceutical pellets were agglomerates of fine powdered particles 
or bulk drugs and excipients, small, free-flowing, spherical or semi-spherical 
solid units, size ranges from about 0.5mm to 1.5mm (ideal size for oral 
administration) obtained from diverse starting materials utilizing different 
processing techniques and conditions.
14 
1.4.1 Desirable properties of pellets
 
Uncoated pellets   
 Uniform spherical shape and smooth surface 
 Optimum size, between 600 and 1000mm 
 Improved flow properties. 
 High physical strength and integrity 
 Good hardness & low friability 
 High bulk density 
 Ease and superior properties for coating 
 Reproducible packing of beds and columns.  
Coated pellets  
 Maintain all of the above properties 
 Contains  active ingredient to keep the size of the final dosage form 
within reasonable limits 
 Have desired drug release characteristics. 
 
 
               Figure 2: 1. Pellets, 2. Perfect pellet, 3. Coated pellet 
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Advantages of pellets 
 The smooth surface and the uniform size of the pellets allows uniform 
coating not only in each pellet but also from batch to batch.Controlled release 
rate can be obtained by coating of pellets with various drugs. 
  For immediate release products, large surface area of pellets achieve 
better distribution. 
  Chemically incompatible products can be formulated into pellets and 
administered  in a single dose by encapsulating them. 
  The beads or granules of different thickness of coatings are mixed in the 
desired proportions to give the desired effect. 
  The rate of release from the drug or contents depends on thickness of the 
coated particles.  
 Improved appearance of the product and the core was pharmaceutically 
elegant. 
 Pellets can be divided into required dosage strengths without process or 
formulation changes and also allows the combined delivery of two or more 
bioactive agents that may or may not be chemically compatible, at the same 
site or at different sites within the git tract. They will offer high degree of 
flexibility in the design and development of oral dosage form like suspension, 
tablet and capsule. 
 Small pellets with the mean diameters below 0.5 mm are most suitable for 
compression into rapidly disintegrating tablets. Such pellets can be produced 
by direct pelletization methods. 
 
 
 12 
 
                                                                                                                                                                                        
                       Figure 3:  Flexibility of pellets in development of dosage forms 
Disadvantages of pellets 
 The manufacturing of (MUPS)multiple unit dosage forms was more 
complicated and expensive. 
 The filling of pellets into gelatin capsules was difficult to accomplish, 
especially in the case where different subunits were  involved.  
 
1.4.2 Theory of pellet formation and growth 
1.4.2.1 Stages in pellet formation and growth 
16,17 
Formation and growth of pellets can be divided into four stages. 
 Pendular state 
 Funicular state Capillary state 
 Droplet state 
Pendular state 
                  The initial step in  process was the  bringing liquid binder into contact 
with powder particles and attempt to distribute this liquid evenly throughout the 
fluidized particles. This leads to formation of initial agglomerates and the stage  
nucleation stage. 
                  When liquid was added in the powder mixture, part of  void space in a 
randomly packed material was filled with a liquid, forming lens-like rings 
 13 
 
(Liquid bridges) at the contact points between the particles forming agglomerates. 
The number of contact points of any particle was  a function of the distribution 
and surface geometry of the adjacent particles. 
                     This state, where the ratio of the liquid to the void volume is low is 
called pendular state. Mutual attraction of particles was brought about by  surface 
tension of the liquid and the negative suction pressure was generated at the liquid 
bridges. 
Funicular state 
                    Like  pendular state, in  funicular state also liquid bridges containing 
gas and pores filled with liquid were present but here the liquid forms a 
continuous phase and pockets of air were dispersed throughout the agglomerate . 
 
Figure 4: Different formal spatial structures of liquid-bound agglomerates. 
Capillary state:                            
                     The capillary state was reached when all the void spaces in 
agglomerate was fully occupied by liquid but the quantity of liquid was not 
sufficient enough to surround the agglomerate. Capillary pressure and interfacial 
forces create strong bonds between the particles, which can disappear if the liquid 
gets evaporated.  
Droplet state 
                      In this state, the liquid completely envelopes the agglomerate. The 
primary particles were held together only by the surface tension of the droplet. 
There was no interparticle capillary bonding and this situation almost never 
happens in fluid beds. 
 
 14 
 
 
1.4.2.2 Elementary Growth Mechanism 
18 
                           The most classified pelletization process involves three 
consecutive regions nucleation, coalescence and layering, abrasion transfer. 
Nucleation 
                          Nucleation occurs whenever a powder is wetted with liquid and 
presents first stage of the pellets growth. The primary particles accumulate to 
form three-phase air-water-liquid nuclei and attached together by liquid bridges 
which are pendular in nature. The size, rate and extent of nuclear formation was 
influenced by size,viscosity,moisture content,wettability and processing 
conditions. 
                  Nucleation was followed by a transition phase with two major 
mechanisms, coalescence and layering.  
 
Coalescence 
                    Coalescence phase was characterized by formation of large-sized 
particles by random collisions of nuclei containing  excess of moisture. Although 
the number of nuclei was reduced, the total mass of the system remains 
unchanged during this step. 
 
Layering 
                     This process involves successive addition of fines and fragments on 
surface of nuclei. The number of nuclei remained to be same but the total mass of 
nuclei in the system increases due to increasing particle size as a function of time. 
The fragments and fines formed during the process of particle size reduction due 
to attrition, breakage and shatter, are picked up by large pellets. Layering 
continues until the number of favourable collisions decreases rapidly, thereby 
leading to a reduction in the rate of growth of the pellets. At this point the third 
phase, the ball growth was reached. 
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 Abrasion transfer 
                       Which involves the transfer of materials from one granule formed 
to another without any preference in either direction. Particles will experience a 
change in size as long as the conditions that lead to the transfer of material exist 
but not change in the total number or mass of the particles. 
 
Figure 5: Pellet growth mechanisms. A. Nucleation, B. Coalescence,  
C. Layering  and D. Abrasion transfer 
 
1.4.3 Pelletization techniques 
                            Pelletization was an agglomeration process that converts fine 
powders or granules of bulk drugs and excipients into small, free-flowing, 
spherical or semi-spherical units, referred to as pellets.Release mechanism and 
release rate from coated pellets depends on film microstructure .This depends on 
coating technique.There are several manufacturing techniques for production of 
spherical pellets.
18,19,20 
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                                Figure 6: Different pelletization techniques 
1.4.3.1 Agitation 
Balling 
            Fine particles are formed upon the addition of appropriate quantities of 
liquid, to spherical particles by a continuous rolling or tumbling motion. Pans, 
discs, drums, or mixers were used to produce pellets by the balling. 
 
1.4.3.2 Compaction
 
a. Compression 
                   Mixtures of API and excipients were compacted under pressure to  
produce  pellets of appropriate shape and size.  
 
b. Extrusion – Spheronization 
                     This was a multistep process invented by Nakahara, in 1964.It 
involves dry mixing of the API with excipients, granulation of wetted mix, 
extrusion of the wet mass, transfer of the mass to spheronizer to get spherical 
shape and drying of the wetted mass in a dryer finally  at the end screening of 
mass to obtain required particle size. 
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Figure 7: Principle of Extrusion – Spheronization process 
 
1.4.3.3   Layering 
                  In this process, drug was deposited onto seed materials  in powder, 
solution or suspension form and leads to heterogeneous pellets with an inner core 
region and an outer shell region of a different composition. This process was 
classified into three types-  direct pelletization, solution or suspension layering 
and powder layering. 
a. Direct pelletization  
                  This process  leads to formation of homogeneous pellets with 
microscopically uniform structure.Direct pelletization was mainly performed in 
high shear mixers and fluidized bed equipment. 
 
                                  Figure 8: Principle of direct pelletizing process 
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b. Powder Layering 
                      It involves the deposition of successive layers of dry powder of 
drug or excipients or both, on previously formed nuclei or cores with the aid of 
binding liquid . Equipment used was tangential spray/centrifugal/rotary fluidized 
bed granulator. 
 
 
 
 
                             
 
Figure 9: Principle of Powder layering procedure 
c. Solution/Suspension layering 
                       In the case of Solution/Suspension layering, growth of pellets 
involves deposition of successive layers of solution and/or suspension of drug 
substance and binders on preformed  nuclei, which may be inert seed, crystal or 
granule. The drug was dissolved or suspended in the binding liquid, with or 
without the binder. Droplets of the binding liquid spread on the surface of the 
nuclei. Liquid evaporates and the dissolved substances crystallizes out during 
drying and the formed capillary forces draw the particles towards each other and 
towards the inert seed, forming solid bridges. 
                       In suspension layering, particles have low solubility and are 
bonded by solid bridges formed from the hardening binder i.e., that high 
concentration of binder was needed. In this process fines were produced as a 
result of attrition or spray drying, especially when the process was not 
optimized.Starter seeds usually used are sugar spheres containing of a sugar-
starch mix or recently MCC pellets and the pure drug crystals were used. The 
most common configuration used was Wurster, bottom spray coater.  
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 Figure 10: Principle of Solution and Suspension layering process 
1.4.3.4Coating equipment 
Conventional coating pan 
                  In this technique the granules were placed in the coating pan and the 
coating solution was sprayed on the granules by atomizer with pressure. 
 
Figure 11:  Conventional coating pan 
  
 20 
 
Fluidized Bed Processing 
a. Hot air pushes beads into coating column.. 
b.While moving through the column, beads were sprayed with coating 
solution. 
c.As beads circulate through the bed, the coating solution dries and leaves a 
layer of  solids on the bead.
18
 
 
Figure 12: Fluidized bed processing 
 
 
1.4.3.4 Globulation  
                    Globulation or droplet includes spray drying and spray congealing.  
 
a. Spray drying 
                    Drug particles in solution or in suspension form are sprayed, with or 
without excipients, into a hot stream of air to generate dry and highly spherical 
particles. It was generally employed to improve the dissolution rates and  
bioavailability of poorly soluble drugs.          
 
b. Spray congealing 
                     In this process drug was allowed to melt, disperse, or dissolve in hot 
melts of gums, waxes, fatty acids, etc., and was sprayed into an air chamber 
where the temperature was below the melting points of the formulation 
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components, to provide spherical congealed pellets under appropriate processing 
conditions. 
1.4.4 Pelletization equipment 
21
 
                       The production of heterogeneous pellets and particle coating was 
carried out in top spraying or different types of bottom spraying fluidized bed 
equipment. 
 
1.4.4.1 Fluidized Bed Processor (FBP)  
                        A fluidized bed system was a unique process for uniform, 
continuous and coating of granulates, pellets and powders. Aqueous or organic 
coatings can be applied. Coating and drying takes place in same machine. 
 
Principle of operation      
                        In FBP, particles are fluidized and the coating fluid was sprayed 
on and dried. Small droplets and a low viscosity of the spray medium ensure an 
even product coating. 
 
Advantages of fluidized bed processor 
 All-in-one process from  powder coating to simple drying.  
 Unique technology that combines  spray behavior with optimum media 
delivery and easy cleaning. 
  Uniform, continuous product coating. Aqueous or organic coatings can 
be done. Coating and drying take place in same machine. In terms of the 
coating process and the filling and emptying of the machine can be carried 
out in complete isolation and without product spreading into the environment.   
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                                          Figure 13: Fluidized bed processor 
 
1.4.4.2 Types of fluid bed systems 
 
 Top spray 
 Bottom spray 
 Tangential spray 
 
Top spray coating  
                   The binder solution was sprayed into the fluid bed from above against 
the air flow (counter current) by using nozzle. Air volume was adjusted to have 
the center of the particle stream very close to the nozzle. Drying takes place as 
the particles to move upwards in the air flow. It was preferred for taste masking 
coating , additionally suitable for the application of hot melt coating. 
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                                           Figure  14: Top spray 
Bottom spray coating  
                    The process was suitable for pellet suspension coating or film/sugar 
coating, particularly useful for a control release active ingredients. In this 
process, a complete sealing of the surface was achieved with a low usage of 
coating substance. Convection was created through the strong force from bottom 
toward top. The granules will fell down and then sucked into the coating column 
again, while bottom spray gun will spray towards top to achieve coating purpose. 
As the particles continues moving upwards, pellets were dried and fall outside of 
the Wurster tube back towards the base plate.Used for  application of modified 
release coatings to a variety of multi particulates and was also suitable for drug 
layering when the drug dose was in the low to medium range. 
  
                                      Figure 15: Bottom spray 
Tangential spray coating (Rotor pellet coating) 
                               In this process the cores were placed on the turntables and hot 
air was blown upward between the turntables and the granulation area. The 
passage of air causes the cores to roll on the turntables. At the same time, the 
coating solution was sprayed on the rolling cores through the pump and spray 
gun.  
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                                                             Figure 16: Tangential spray  
 
                This process involves simultaneous coating and drying of the cores, 
layer after layer, till it achieves the required coating thickness or granule size.  
  
     Figure 17: Spin flow of rotation plate in tangential spray coating 
 
 
1.4.5 Excipients for pellets 
18
 
                                 Excipients were added to pharmaceutical dosage forms  to 
produce satisfactory delivery of  drug to the intended site, to impart favourable 
characteristics to the dosage form. Since pellets were administered orally,  
excipients used in the pellets are typically the same as those used in tablet or 
capsule formulations. 
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Filler  MCC, Starch, Sucrose, Lactose, Mannitol 
Binder Gelatin, HPC, HPMC, MC, PVP, Sucrose, Starch 
Lubricant Calcium stearate, Glycerin, PEG, Mg stearate 
Separating agent Kaolin, Talc, Silicon dioxide 
Disintegrant Alginates, Croscarmellose sodium 
pH adjuster Citrate, Phosphate, Meglumine 
Surfactant Polysorbate, Sodium lauryl Sulphate 
Spheronization enhancer MCC , Sodium carboxy methyl cellulose 
Glidant Talc, Starch, Magnesium stearate 
Release modifier Ethyl cellulose, Carnauba wax, Shellac 
Table  1: Examples of commonly used excipients 
 
 
1.4.6 Coating of pellets
21,22 
                    Coating can be applied for the following reasons: 
 For masking of the taste, odor or color of  drug. 
 To provide physical and chemical protection to the drug. 
 To control the release characteristics of the drug. 
 To protect the drug from gastric environment. 
 To incorporate another drug or formula adjuvant in the coating to avoid 
chemical incompatibility or to provide sequential drug release. 
 To provide pharmaceutical elegance by using of specific color. 
 
 
Types of Coating 
 Sugar coating 
 Film coating 
 Enteric coating 
 Extended release coating 
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1.5 Capsules 
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                    Capsules are solid dosage forms in which the drug or a mixture of 
drugs was enclosed in hard or soft gelatin capsules. These shells are made up of 
gelatin and are intended for oral administration. These are available in various 
sizes, shapes and capacity. 
 
Advantages of capsules  
1.Ease of use because they are smooth, slippery and easy to swallow. 
 2.Bitter taste and unpleasant odored drugs can be masked by keeping in a 
capsule. 
 3.As produced in large quantities it was economic, attractive and available in 
wide range of colors. 
 4.Minimum excipients required. 
 5.Unit dosage form. 
 
Disadvantages of capsules 
 1. Not suitable for highly soluble materials like potassium chloride, potassium 
bromide and  ammonium chloride, etc. 
 2.Not suitable in case of highly Efflorescent or Deliquescent materials. 
 3.Special conditions were required for storage. 
 
 
1.5.1 Types of capsules 
      1. Hard gelatin capsules 
      2.  Soft gelatin capsules 
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1.5.1.1 Hard gelatin capsules 
                          These sizes are designed by in numbers. 
                            
 
S.No 
 
Size of capsules 
 
Volume in ml 
 
Fill weight in mg 
 
1 
 
000 
 
1.37 
 
615-1370 
2 00 0.95 430-950 
3 0 0.68 305-680 
4 1 0.50 225-500 
5 2 0.37 165-370 
6 3 0.30 135-300 
7 4 0.21 95-210 
8 5 0.13 60-130 
Table 2: Capsules sizes and their fill weights 
1.5.1.2 Soft gelatin capsules 
                        These are classified depending upon the sizes and capacities. 
The number represents capacities in minims 
a. Round-1,2,3,4,,5,6,7,8,9,28,40,40T,80T and 90T. 
b. Oval-1,2,3,4,,5,6, 7..5,10,12,16,20,40,60,80,85 and 110. 
c. Oblong-3,4,5,6,8,9.5,11,14,16,20,90 and 360. 
d. Tube-5,6,8,17.5,30A,30B,35,45,55,65,90,160,250,320 and 480. 
e. Misc-6, 17, 30, 35, 60 and 80. 
 
1.5.2 Capsules Standards and limits: 
1. Description: It should comply with specifications of product. 
2.Content of active ingredient: Limit: 90 to110% of label claim or as per In 
house limit. 
 28 
 
 
3.Uniformity of weight                         
Average weight of 
capsules content 
 Percentage deviations 
allowed 
less than 300mg 10% 
300mg or more 7.5% 
Table 3: Content uniformity limits 
 
4. Standard length for hard gelatin capsules in mm                                            
 
 
 
 
 
 
Table 4 :Capsules lock length in mm. 
 
iv. Disintegration test 
a. Hard gelatin capsules: Disintegration time should not be more than 45 min. 
b. Soft gelatin capsules: Disintegration time should not be more than 60 min. 
c. Enteric capsule: Acidic media –should not disintegrate in 2hrs and in 
alkaline medium capsules shall disintegrate within 30 min. 
6. Microbial limits: Total microbial count, not more than 1000%gram of the 
capsules shell. One gram of capsules shall be free from E.coli and Salmonella. 
Size Cap Body 
0 10.68-11.68 18.22-19.22 
1 9.51-10.51 16.22-17.22 
2 8.67-9.67 14.84-15.84 
3 7.73-8.73 12.98-13.98 
4 6.97-7.97 11.840-12.84 
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7. Loss on drying: Between 12.5% and 16% detrained on 0.3 gram of shell by 
drying in oven at 105
0
C for 4 hrs or to constant weight.       
1.5.3 Evaluation tests for capsules 
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The various evaluation tests for capsulesare as follows. 
1. Stability tests 
2 .Invariability tests 
3. Disintegration test 
4. Dissolution test 
5. Moisture permeation test 
1. Stability tests 
                  Stability tests for capsules are performed to know the integrity of 
gelatin capsule shell and for determining the shelf life of capsules.                                                                                           
Stability tests include:                                                                                                                         
A.Shell integrity test                                                                                                                        
B. Determination of shelf life  
A. Shell integrity test:                                                                                                                  
This test is performed to find out the integrity of capsule shells.                                                                                                                 
Relative humidity Temperature Type of container 
80% Room temperature Open 
- 40
0
C Open 
- 40
0
C Tightly closed 
Table 5: specifications for shell integrity test. 
 
Method:                                                                                                                                                                               
The capsules which are to be tested and the standard capsules are placed in one 
of the above conditions for the two weeks with periodic examination. The gross 
and the net changes occurring in them are as follows. 
i.The standard capsule shells kept at the room temperature and 80% RH become 
more soft, sticky and swollen. 
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ii. The test capsules kept under the same conditions undergo the following 
changes: 
 Gross changes include colour fading, discolouration, disintegration, leaking and 
turning brittle or soft. 
 Net changes include loss of volatile ingredients, grooves growing darker and 
wider and a little change in colour of the shell. 
B. Determination of shelf life 
                 Shelf life of packed capsules is determined under normal conditions. 
2. Invariability tests 
                 The invariability in the medicaments packed in the capsule shells can 
be determined by performing the following tests. 
a.Weight variation test 
b.Content uniformity test 
a. Weight variation test 
Weight variation test for hard gelatin capsules 
 Individually weigh twenty filled capsules and determine their average weight. 
 Calculate the weight variation of every capsule against the average weight. 
 If the variation exceeds ± 10%, then determine the actual weight of the 
medicament separately and compare it with the overall average weight. 
 If the overall average weight of 2-6 capsules differ by ±10% to ±25%, then 
repeat the same procedure with 40 more capsules. 
 When 60 capsules are taken for test, only six capsules can differ from the overall 
average weight more than 10%. In no case they should differ more than ±25%. 
Weight variation test for soft gelatin capsules 
 Individually weigh 10 filled capsules. 
 Empty the contents of the capsules by washing with suitable solvents. 
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 Allow the solvents to evaporate from the contents at room temperature for about 
half-an- hour. Take necessary steps to prevent the uptake or/ and loss of 
moisture. 
 Net contents are calculated by weighing the empty capsule shell separately. 
 Finally, the contents of therapeutically active ingredient are determined from the 
outcome of the assay directed in the individual monograph in pharmacopeia. 
b. Content uniformity test 
                      At first, 10 capsules are assayed individually to determine the 
percentage purity of the active ingredient. 9 out of these 10 capsules should be 
within the range of 85-115%.in case 1-3 capsules are outside the standard range, 
then additional tests are performed on the remaining 20 capsules. The net result 
of the 30 capsules assayed should prove that atleast 27 capsules are within the 
desired extremes i.e. between 85 and 115 % and no capsule is beyond the stated 
range i.e., between 75 and 125%. 
3. Disintegration test   
                       Disintegration test is carried out in the disintegration test 
apparatus. A capsule is placed in every glass tubes is positioned in the beaker 
containing the required fluid such that all the capsules dip properly. The 
apparatus is then operated for specified time. The capsule passes the 
disintegration test when none of the drug particles remain on the mesh/wire 
screen i.e., the capsule must disintegrate and all the particles must pass through 
the mesh within the time specified in the monograph. However, the insoluble 
coating particles or the soft mass without palpable core are exempted. 
Note: If one or two capsules do not disintegrate in the specified time, then the 
test is repeated with 12 more capsules. The net result of 18 capsules tested for 
disintegration should prove that at least 16 are disintegrated within the specified 
time. 
                    According to USP, the disintegration time of capsule is 45 min. 
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4.Dissolution test 
                    The USP has mentioned about seven different apparatus designs for 
dissolution testing. Among these, apparatus-1 and apparatus-2 are of primary 
importance. 
                 When one capsule is tested, the amount of dissolved drug in the 
solution is calculated as a percentage of the amount of dissolves active 
ingredient (P) specified in the individual monograph. 
                 When more than one capsule are being tested, the dissolution test is 
carried out through three stages. 
Stage 1 T1: 
                  Test six capsules and are accepted if each of them is not less than the 
monograph specified limit +5% i.e., P+5%. 
Stage 2 T2: 
                   If the dosage form fails the T1, then additional six capsules should 
test. The result is acceptable if the average of the 12 capsules is greater than or 
equal to P, and none of them is less than P-15%. 
Stage 3 T3: 
                   If capsule still fails the test, then additional 12 capsules should test 
and are accepted if the average of all the 24 is greater than or equal to P, if not 
more than two are less than P-15% and none of them is less than P-25%. 
5. Moisture permeation test   
                    For performing this test, one capsule in the single unit container or 
the unit dose container is packaged along with the dehydrated pellets, which 
have the property of changing colour in the presence of moisture. The packaged 
capsule is then placed for a certain period of time in an atmosphere of known 
humidity. Any change in the colour of dehydrated pellets reveals the absorption 
of moisture. The weight of this test capsule is then compared with the weights of 
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the capsules under test. The difference in weights gives the amount of moisture 
absorbed. 
 
1.6 Attention deficit hyperactive disorder (ADHD) 
25
 
                          
                           The definition of ADHD based on mal adaptively high levels of 
impulsivity, hyperactivity and inattention. They are all based on observations 
about how children behave, ‘impulsivity’ signifies premature and thoughtless 
actions, ‘hyperactivity’ a restless and shifting excess of movement, and 
‘inattention’ is a disorganized style preventing sustained effort. 
 
1.6.1 Common problems associated with ADHD 
                       It was very common for the core problems of ADHD in children to 
present together with other developmental impairments and/or mental health 
problems. There are many non-specific problems that were observed in ADHD 
were motor tics, mood swings, unpopularity with peers, clumsiness. 
Young and adult people shows some problems,which are self-harm, a 
predisposition to road traffic accidents, substance misuse, delinquency, anxiety 
states and academic underachievement, similarly they are not in themselves 
grounds for the diagnosis and may result either from ADHD or from other 
causes. 
 
1.6.2 Changes with age 
                      The problems associated with ADHD appear in different ways at 
different ages, as the individual matures and as the environmental requirements 
for sustained self-control increase. Hyperactivity in a pre-school child, during the 
school years an affected child may make excess movements during situations 
where calm was expected. During adolescence hyperactivity was present as 
excessive fidgetiness rather than whole body movement. In adult life it may be a 
sustained inner sense of restlessness and inattention. 
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1.6.3 Course of the disorder 
Onset 
                      The core behaviors of ADHD were typically present from before 
the age of 7 years, but at all ages presentation as a problem was very variable. 
Mild forms need not be impairing at all. Extreme forms are considered to be 
harmful to the individual’s development. While both teachers and parents can 
find it hard to deal with or live with a hyperactive child, their tolerance and 
ability to cope may determine whether the hyperactivity was presented as a 
problem. Children with hyperactivity rarely ask for help themselves. Inattention 
without hyperactivity often was not present as a problem even though an 
inattentive child may have a marked cognitive impairment. The presentation to 
the clinician therefore depends on a complex blend of the skills and tolerance of 
adults surrounding the child and the qualities of the children themselves. 
 
Course and impairment 
                     The core problems of ADHD and the associated features can persist 
over time and impair development in children. Several studies have followed 
diagnosed schoolchildren over periods of 4 to 14 years, all have found that they 
tend to show, by comparison with people of the same age who have not had 
mental health problems, persistence of hyperactivity and inattention, poor school 
achievement and a higher rate of disruptive behaviour disorders.  
                       
                        Longitudinal population studies have shown that hyper active 
impulsive behaviour was a risk for several kinds of adolescent maladjustment . 
Lack of friends, work and constructive leisure activities were prominent and 
affect the quality of life. Severe levels of hyperactivity and impulsivity also make 
children more likely to develop an antisocial adjustment and more likely to show 
personality dysfunction or substance misuse in later adolescence and adult life. 
Although ADHD symptoms persist in the majority of cases, it was important to 
remember that many young people with ADHD will make a good adjustment to 
adulthood and be free of mental health problems.  
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1.6.4 Diagnosis  
Diagnostic systems and criteria 
                        The most commonly used criteria for the diagnosis of both 
children and adults are those provided in DSM-IV-TR and in ICD-10. 
                        The DSM criteria break down symptoms into two groups: 
inattentive and hyperactive-impulsive. Six of the nine symptoms in each section 
must be present for a ‘combined type’ diagnosis of ADHD. If there are 
insufficient symptoms for a combined diagnosis then predominantly inattentive 
(ADHD-I) and hyperactive (ADHD-H) diagnoses are available. The ICD uses a 
different nomenclature, the same symptoms were described as part of a group of 
hyperkinetic disorders of childhood, and inattention, hyperactivity and 
impulsivity must all be present, so only ‘combined-type’ ADHD qualifies.  
DSM-IV-TR criteria for attention deficit hyperactivity disorder 
1. Either A or B. 
A. Inattention – Six or more symptoms persisting for at least 6 months to a 
degree that was maladaptive and inconsistent with developmental level. 
 Failure of close attention to details and makes careless mistakes in 
schoolwork, work, or other activities. 
 Lack of attention in tasks or play activities. 
 Often should not  listen when spoken to directly. 
 Often should not follow on instructions; failed to finish schoolwork, 
chores or workplace duties (not due to oppositional behaviour or failure to 
understand instructions). 
  Difficulty in organising tasks and activities 
 Often avoids, dislikes, or was reluctant to do tasks needing sustained 
mental effort. 
 Often loses things necessary for tasks or activities. 
 Is often easily distracted by extraneous stimuli. 
 Is often forgetful in daily activities. 
B. Hyperactivity-impulsivity – 6 or more symptoms persisting for at least 6 
months to a degree that was maladaptive and inconsistent with developmental 
level. 
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Hyperactivity 
 Often fidgets with hands or feet or squirms in seat. 
 Often leaves seat in classroom or in other situations where remaining 
seated was expected. 
 Often runs or climbs excessively where inappropriate (feelings of 
restlessness in young people or adults). 
 Often had difficulty in playing or engaging in leisure activities quietly. 
 Was often ‘on the go’ or often acts as if ‘driven by a motor’. 
  Talks excessively. 
 
Impulsivity 
 Often burst out with answers before questions was completed. 
 Often had difficulty in awaiting turn. 
 Often interrupts or intrudes on others (for example, butts into 
conversations or games). 
2. Some hyperactive-impulsive or inattentive symptoms which causes impairment 
were present before age 7 years. 
3. Some impairment from symptoms was present in two or more settings (for 
example, at school or work and at home). 
4. There must be the clear proof of significant impairment in social, school or 
work functioning. 
5. The symptoms do not happened only during the course of a pervasive 
developmental disorder, schizophrenia or other psychotic disorder. The 
symptoms were not better accounted for by another mental disorder (for example, 
mood disorder, anxiety disorder, dissociative disorder, or a personality disorder). 
 
1.7 Psychostimulants 
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                       Psychostimulants were the most commonly used medications for 
the treatment of ADHD in college students and are helpful in greater than 70% of 
students with ADHD.Nearly an equal percent of students with ADHD can 
respond to medications in the methylphenidate group or the amphetamine group 
of drugs. Some persons who can’t  tolerate or respond well to drugs from 1 group 
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will respond better when given a medication from the other class of 
psychostimulants. 
 
Methylphenidate 
                       Methylphenidate (MPH), a Schedule II medication, has been a 
standard part of ADHD treatment. The mechanism of action of MPH was 
believed to be its ability to increase the levels of both the norepinephrine and 
dopamine neurotransmitters by increasing release into the extraneural space and 
blocking uptake.   
 
Amphetamines 
                        Initially amphitamines were used primarily for the hyperkinetic 
behavior of minimal brain dysfunction but later they are used to help with the full 
ADHD spectrum of distractibility, hyperactivity, and impulsivity. As with MPH, 
amphetamines were believed to have a clinical benefit primarily because they 
increases the levels of the neurotransmitters dopamine and norepinephrine, block 
their uptake, and increase their release. Adderall  mixture of salts of both d and l 
amphetamine in 75%:25% ratio was superior to the d enantiomer 
dextroamphetamine alone. The onset of clinical effects from Adderall assumed to 
be less abrupt than with Methylphenidate, and the effects were of slightly longer 
duration. Methamphetamine (Desoxyn) was a psychostimulant approved for the 
management of ADHD, but it was considered to be less effective behaviorally in 
ADHD than the d and l- amphetamine preparations. It was also considered to 
have a higher risk for abuse than the other psychostimulants. It was not 
recommended for use in the college setting or for other adults. 
Bupropion 
                  Bupropion was an antidepressant medication of racemic mixture that 
was sometimes used for ADHD. It has been approved by the Food drug 
administration  for use as an antidepressant in children, adolescents, and adults, it 
was not classed as a psychostimulant. Postulated pharmacologic mechanisms of 
action included was inhibition of the uptake of neurotransmitters serotonin, 
dopamine, and norepinephrine. The effects may be weaker than those from the 
psychostimulants.              
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                                             Literature Review 
 
1.Hara et al.,
27
(2011)
 
A pharmaceutical patch with superior stability of a drug 
(methylphenidate), skin permeability of a drug during use of patch, and 
methylphenidate bioavailability is provided. A patch comprises a support and an 
adhesive layer formed on at least one surface of the support, wherein the adhesive 
layer contains methylphenidate and/or a salt thereof, polyisobutylene and a 
liq.plasticizer. The liq.plasticizer preferably has an HLB value of 1.0-3.3. Thus, a 
patch was prepared by applying to a polyethylene terephthalate release liner a 
compound containing methylphenidate blend with an adhesive containing 
polyisobutylene of two mol.wts (55,000 and 4,00,000) and polybutene as a 
tackifier, and iso-prpalimitate as a liq.plasticizer.The methylphenidate patch 
showed good stability even under harsh preservation conditions at 60,high drug 
permeation rate through human skin, and methylphenidate bioavailability of 
66.4%.   
 
2.Abdhul Althaf.s et al.,28(2011) The present study was conducted to develop a 
pharmaceutically equivalent, stable, cost effective and quality improved 
formulation of Ambroxol pellets to present it in the form of capsules (Modified 
release capsules). To achieve this goal various prototype formulation trails were 
taken and evaluated with respect to the various quality control such as 
dissolution, assay, acid resistance and moisture content. The active 
pharmaceutical ingredient Ambroxol was subjected to preformulation study, and 
the results obtained with selected excipients showed good compatibility with 
Ambroxol. Ambroxol coated pellets were formulated by using commercially 
available pellets and Ambroxol coated pellets were filled by capsule filling 
machine. The stability of the capsules and pellet was determined by conducting 
“Accelerated stability testing” in 40°C ± 2°C / 75% ± 5%RH, 30ºC ± 2 ºC/ 65% 
± 5% RH and 25±2°C/60±5% RH conditions for 1 month. Finally, after the 
duration, the product was analyzed for content and dissolution study. By the 
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stability studies, the formulated Ambroxol modified release capsules and pellets 
proved to be stable throughout the period of the storage. 
 The Ambroxol modified release pellets were loaded in size 4 capsules. It 
showed good results in formulation of stable dosage. Modified release pellets 
have minimum volume in size, greater surface area and more surface of 
disintegration time for pellets in capsules. Small volumes of pellets enter into 
the systemic circulation very fast.Moreover no accumulation of drug in the body 
occurs. 
 
3.Fleshner-Barak et al.,
29
(2010)
 
The present invention provides a 
pharmaceutical composition for use in a dosage form for oral administration to a 
patient. The composition expands upon contact with gastric fluid and promotes 
retention of the dosage form in the patient’s stomach for a prolonged period of 
time. The dosage forms may be used advantageously in the treatment of 
Parkinson,s disease with levodopa and hyperactivity and attention deficit disorder 
with methylphenidate. Thus, tablets containing 10% methylphenidate and Klucel 
LF,starch,MCC,SSG, and mg.stearate were prepared and coated with a 
composition containing Et.cellulose,urea,and tri-Et citrate in ethanol. Tablets can 
adhere to GRDS and burst release of drug takes place. 
 
4.) Kotta Kranthi Kumar et al.,30(2010)In recent years scientific and 
technological advancements have been made in the research and development of 
controlled release oral drug delivery systems by overcoming physiological 
adversities. There are so many oral delivery systems in that one of the advance 
techniques is Pellatization. Indomethacin extended release capsules prepared by 
pellatization method that the indometahcin is coated on inert sugar spheres by 
using povidoneK-30 as a binder solutions and Hydroxypropylmethylcellose, 
Ethyl cellose coating agents used for extended release action. The prepared 
capsules were evaluated for content uniformity weight variation, in-vitro 
disintegration time, assay, and in-vitro drug release study. All the formulation 
exhibited assay, content uniformity with in the range given in USP. Dissolution 
studies revealed that formulations containing Cross povidone-k 30 2.31gm 
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coating agent Hydroxypropylmethylcellose, 0.312gm of ethyl cellose 0.216gm 
Showed 100% of drug release, at the 12th hour. The concentration of coating 
agents Hydroxtpropylmethycellose and Ethyl cellose had an effect on in-vitro 
drug release had the same drug release profile when compare with US 
dissolution parameters, and reference drug release. Thus, the capsules apart 
from fulfilling all official and other specifications and exhibited higher rate of 
drug release. 
 
5.Parmindersingh et al.,
31
(2009)
 
Passive and electrically assisted transport 
(iontophoresis) of  Methylphenidate from aqueous Methylphenidate 
hydrochloride solutions across excised human skin were studied. Based on in-
vitro flux data, the daily dose of 15-40mg Mph delivery can be achieved using 
current denisity of 0.5mA/cm2 with minimum transport area. Iontophoresis 
significantly enhanced protonated methylphenidate transport as compared with 
passive delivery. 
 
6.Russell Schachar et al.,
 32
 (2008) Pharmacodynamics of multilayer release 
methylphenidate(once per day) with IR methylphenidate(twice per day) or 
placebo in patients with attention deficit /hyperactivity disorder were 
compared.MLR MPH showed equivalent improvments in behavioral and 
cognitive measures and has a duration of effect at least as long as that of IR MPH 
given twice daily and side effects are reduced with MLR MPH. 
 
7.Robert L. Findling et al.,
 33
 (2008)
 
Efficacious and well-tolerated medications 
are available for the treatment of attention deficit/hyperactive disorder (ADHD). 
Stimulants such as Methylphenidate and amphetamines are the most widely used 
medications approved by the US Food and Drug administration for the treatment 
of ADHD in children. Many studies have reported the long term efficacy and 
tolerability of immediate release formulations of MPH. The disadvantage of such 
formulations include the need for multiple daily dosing and a potential for abuse. 
An extended release formulation of  dexomethylphenidate and mixed 
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amphetamine salts has been reported to be well tolerated and efficacious. The non 
stimulant atomoxetine has been well tolerated, although it may not be as effective 
as stimulants.  
8.Kim TW et al., 
34 
 (2007) Studied a drug containing polymeric dispersion was 
applied onto nonpareil sugar spheres (18/20 mesh) using a fluid-bed spray coater. 
Eudragit RS30D was selected as the polymeric coating material. Melatonin used 
as model drug. The release behaviors of the coated sugar spheres were 
investigated in gastric fluid (pH 1.4) for 2h,and then continuously in intestinal 
fluid (pH 7.4) for 14h.The release rate of coated sugar spheres decreased with 
increasing coating levels. The solvent (ethanol) in the coating dispersions 
significantly decreased the release of the drug due to the good dispersion of the 
low solubility melatonin in the polymeric films. The polymer (PVP) and drug 
contents in the coating dispersions did not affect the release rate. The release 
profiles were drastically changed according to the type and concentration of 
plasticizers used.  
 
9.Hardy IJ et al.,
 35
 (2007)
 
studied modulation of drug release kinetics from 
HPMC matrix tablets using PVP. The study presents a simple, cost effective and 
elegant solution for achieving a range of predictable release profiles from linear 
to bimodal for a water-soluble drug (Caffeine) form HPMC matrices through the 
inclusion of PVP. Mechanistic studies using gel rheology,excipient dissolution 
and near infrared microscopy are presented which shows the modulation of drug 
release 
 
10.Harris Shoaib M et al.,
 36
 (2006) studied the evaluation of drug release 
kinetics from Ibuprofen matrix using HPMC. Different dissolution models were 
applied to evaluate drug release mechanism and kinetics. The drug release data 
fit well to the Higuchi expression. Drug release mechanism as a complex 
mixture of diffusion, swelling and erosion. 
 
11.Devane et al.,
 37
 (2006) The invention relates to a multiparticulate modified 
release composition that, upon administration to patient, delivers at least one 
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active ingredient in a bimodal or multimodal manner. Multiparticulate modified 
release composition comprised (i) an immediate release component containing 
Methylphenidate Hydrochloride, Microcrystalline cellulose ,lactose ,povidone 
and (ii) a modified release matrix containing Methylphenidate Hydrochloride, 
Microcrystalline cellulose, Eudragit RS and povidone. The bioavailability of 
Methylphenidate Hydrochloride was evaluated in a human crossover based,fasted 
healthy volunteers dosed with 20mg Methylphenidate Hydrochloride 
composition. The plasma profile was equal similar to the control which consisted 
of two 10mg doses of IR given twice at a 4h interval. 
 
12.W.Brayan Staufer et al.,
 38
 (2005)
  
Studied that, Methylphenidate (MPH), a 
Schedule II medication, has been a standard part of ADHD treatment for the past 
four decades. MPH shares common effects and side effects with the other 
stimulant medications. The mechanism of action of MPH is believed to be its 
ability to increase the levels of both the norepinephrine and dopamine 
neurotransmitters by increasing release into the extraneural space and blocking 
uptake. Clinical effects of immediate release forms of MPH may be noticed 
within 30 to 40 minutes, and maximum blood levels are reached in 1.5 to 2 hours. 
Taking this medication with meals delays absorption slightly, which may mitigate 
some of the side effects. Absorption from the regular tablets is maximized when 
the medication is taken with a high-fat meal. Most of the drug is metabolized to 
ritalinic acid and excreted through the kidneys. 
 
13.Cho Sun Hang et al.,
 39
 (2004) The present invention relates to a sustained 
release drug delivery system composed of a water insoluble polymer, and more 
particularly, to a sustained release drug delivery system comprising: a crystalline 
core material; an active ingredient layer which is formed on an outer surface of 
the crystalline core material and comprises a pharmacologically active ingredient 
and a water insoluble polymer; and a sustained release layer . 
14.M. Dopfner Ph.D. et al.,
 40
 (2004)  This investigation was conducted to assess 
the efficacy and the duration of action of a new extended-release formulation of 
methylphenidate (MedikinetR retard) as a once-daily treatment for children with 
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attention-deficit hyperactivity disorder (ADHD). Method was a 
randomized,double-blind, crossover multicenter study with three treatment 
conditions: once-daily extended-release methylphenidate, twice-daily immediate-
release methylphenidate and placebo. Once a day extended-release 
methylphenidate was not different from the same dose of twice daily immediate-
release methylphenidate. These data provide support for the benefit of this novel, 
once-daily methylphenidate preparation in the treatment of ADHD. The longer 
duration of action of Medikinet Retard has the potential to simplify 
psychostimulant treatment, thus reducing dose diversion and eliminating  the need 
for in-school administration. 
 
15.Yanfeng Wang et al.,
 41
 (2004)
   
Evaluated the in vitro dissolution and in vivo 
absorption of d,l-threo-methylphenidate (MPH) from a novel bimodal release 
formulation (Ritalin LA capsule) compared with an immediate-release 
formulation (Ritalin IR tablet) in healthy volunteers. The bimodal release 
formulation contains 50% of the dose in the immediate-release (IR) beads and 
50% in polymethacrylate-coated, delayed-release (DR) beads. The rate and extent 
of oral absorption of MPH were evaluated based on the overall Cmax, Tmax and 
AUC values, as well as the Cmax, Tmax and AUC values for each individual 
peak of the bimodal plasma concentration-time profile. The in vivo absorption-
time profile was also examined by deconvolution. Ritalin LA formulation 
demonstrated bimodal plasma concentration– time profiles with two peak 
concentrations observed at 2 and 6 h post dose, mimicking that of Ritalin IR 
tablets given 4 h apart. Deconvolution results showed that the absorption of MPH 
was biphasic, with a rapid absorption phase between 0 to 2 h, and a somewhat 
slower second absorption between 3-6 h, consistent with the in vitro bimodal 
release characteristics of Ritalin LA formulation. 
 
 
16.Scott et al.,
 42
 (2003) Studied the use of psycho stimulants to treat attention 
deficit/ hyperactivity disorder has been controversial for a number of reasons. 
Methylphenidate produces behavioral effects associated with abuse potential as 
assessed by traditional assays. Neuropharmacologic data suggest that 
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Methylphenidate has pharmacokinetic properties that reduce its abuse potential as 
compared with other stimulant drugs of abuse, such as cocaine. 
 
17.Evdokia S. Korakianiti et al.,
 43
 (2000) Studied the optimization of the 
pelletization process in a fluid bed rotor granulator using experimental design. 
This study examined the effect of rotor speed, amount of water sprayed, and 
atomizing air pressure on the geometric mean diameter and geometric standard 
deviation of pellets produced in a fluid bed rotor granulator using a 2
3
 factorial 
design and an optimization technique. The size of the pellets was found to be 
dependent on the amount of water added, while an increase in rotor speed 
decreased their size. Both factors were found to be statistically significant 
(P<0.05). The effect of atomizing air pressure on pellet size was statistically 
significant. 
 
18.Ranjani V Nellore et al.,
 44
 (1998) Developed model extended-release 
matrix tablet formulations for Metoprolol tartrate. Different grades of HPMC 
K4M, K15M, K100M and K100LV were used.Three granulation processes were 
employed for the preparation of tablets. In vitro drug release testing was 
performed in pH 6.8 phosphate buffer using USP apparatus type II at 50 rpm. 
The study results suggested that HPMC K100LV can be used as the hydrophilic 
matrix polymer and fluid-bed granulation as the process of choice for further 
evaluation of critical and noncritical. 
 
19.G.M.Clarke et al.,
 45 
(1995) Studied the comparative gastrointestinal transit of 
pellet systems of varying density. The purpose of this study was to examine the 
gastrointestinal transit of multiple unit formulations of densities 2.0 and 2.4 g cm
-
 
3
, comparing both with a control formulation of density 1.5 g cm
-
 
3
. The result of  
these studies have indicated that for densities up to 2.4 g cm
-
 
3 
there is no 
difference in gastrointestinal transit of pellets of size 1.18-1.4 mm  to that of a 
standard control multiple unit formulation  of density 1.5 - 1.7  g cm
-
 
3
. 
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20.M.F.Saettone et al.,
 46 
(1995)
 
Studied the effect of different polymer 
plasticizer combinations on ‘in vitro’ release of theophylline from coated pellets. 
The present investigation evaluated the influence of different plasticizer/polymer 
combinations on theophylline (TH) release from pellets coated with latex 
aqueous dispersions of ethyl cellulose (EC) or acrylic polymers (ACR). The 
plasticizers, present in the coating films in amounts ranging from 8 to 30%, were 
acetylated monoglycerides (AMG), diethyl phthalate (DEP), dibutyl phthalate 
(DBP) and dibutyl sebacate (DBS). The release profiles of TH from the coated 
pellets were influenced by the type and amount of plasticizer and of coating 
material, and by the ratio polymer-plasticizer. For both types of coating, the drug 
release rate decreased with increasing plasticizer content. A correlation was 
found between the permeability coefficients (Pwv) to water vapour of free films, 
having the same composition as those used for coating, and drug release. 
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Aim and Objective 
            
                         
                          Aim of the present investigation was to develop the formulation 
of  Methylphenidate Hydrochloride extended release pellets  using  pelletisation  
technique.         
                           
                            The objective of the study was to clarify the effect of different 
polymers like Ethyl cellulose N-45, PVP k30, PEG6000 and HPMC E5 on 
dissolution properties of the drug.    
                         
                            The optimized formulation was subjected to evaluation tests and 
stability studies.                            
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Drug Profile
 47,48
 
 Methylphenidate Hydrochloride 
                    A central nervous system(CNS) stimulant most commonly used  in 
the treatment of attention-deficit disorders in children and for narcolepsy. 
            Description 
                              White to off-white powder  
            Synonyms 
d-Methylphenidate HCl, Methyl phenidyl acetate, Methylphenidate HCl,                  
Methylphenidate  hydrochloride, Methylphenidatum, 
Methylphenidylacetatehydrochloride, metilfenidat hydrochloride 
           IUPAC Name 
                                 Methyl 2-phenyl-2-(piperidin-2-yl)acetate hydrochloride  
            Chemical Formula 
                                    C14H19NO2.Hcl 
            Category 
                             CNS stimulant 
           BCS  
                      class I 
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 Structure: 
 
                                           Figure:18  Methylphenidate Hydrochloride                                
Molecular Weight: 269.77 g/mol 
 Melting Point: 214-226
o
C                
 Solubility: 
                            It is freely soluble in water and in methanol, soluble in alcohol, 
and            slightly     soluble   in chloroform and in acetone. 
   Pharmacokinetics        
   Absorption 
                   Absorbed readily in a biphasic manner. It reaches peak absorption      
approximately in two hours for the first phase and five hours for the second phase. 
Bioavailability is low (approximately 30%). 
     Distribution 
              Binding to plasma proteins was low (10%-33%). The volume of 
distribution was 2.65±1.11 L/kg for d-methylphenidate and 1.80±0.91 L/kg for l-
methylphenidate. 
    Metabolism 
                  Methylphenidate was metabolized primarily by de-esterification process 
in to ritalinic acid (α-phenyl-2-piperidine acetic acid, PPAA), which has little to no 
pharmacologic activity.Site of metabolism was liver. 
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Excretion 
                  After absorption, Methylphenidate was mainly excreted as ritalinic 
acid(a de-esterified product) by urine , 78 to 97% of the dose was excreted in the 
urine and 1 to 3% in the feces. 
      Elimination half-life:  2.4 hours in children and 2.1 hours in adults. 
      Pharmacodynamics 
     Pharmacology 
                   Methylphenidate was a central nervous system stimulant used most  
commonly in the treatment of attention-deficit disorders in children and for 
narcolepsy. Its mechanisms appear to be similar to those of dextro amphetamine. 
     Mechanism of action 
                  Methylphenidate blocks  reuptake of dopamine and norepinephrine in 
central adrenergic neurons by blocking dopamine transport or carrier proteins. 
Methylphenidate acts at the brain stem arousal system and the cerebral cortex and 
causes increased sympathomimetic activity in the central nervous system.It may 
results in alteration of serotonergic pathways via changes in dopamine transport. 
   Dosage 
               5-30 mg twice a day or up to 60mg per day 
   Toxicity 
                Symptoms of overdose include Vomiting, Agitation, Tremors, 
Hyperreflexia, Muscle twitching, Convulsions (may be followed by Coma), 
Euphoria, Confusion, Hallucinations, Delirium,Diaphoresis, Sweating, Flushing, 
Headache, Hyperpyrexia, Tachycardia,Alopecia,Loss of appetite, Palpitations, 
Cardiac arrhythmias, Hypertension, Mydriasis, and Dryness of mucous membranes. 
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  Partition Coefficient 
                                  log P =2.25  
  Dissociation Constant   
                                   pka=8.77 
   Purity: ≥98%. 
   Therapeutic Class 
 Dopamine uptake Inhibitors  
 Adrenergic uptake Inhibitors  
    Central Nervous System Stimulants 
     Storage 
                   Store in air tight containers, Protect from sun light and moisture,  at a  
temperature below 40
o
C. 
     Indication  
                   For use as an integral part of a total treatment program which typically 
includes other remedial measures (psychological, educational, social) for a 
stabilizing effect in children with a behavioral syndrome characterized by the 
following group of developmentally inappropriate symptoms: moderate-to-severe 
distractibility, short attention span, hyperactivity, emotional lability, and 
impulsivity. 
     Special Populations 
     Age  
           The pharmacokinetics of Methylphenidate was examined in 18 children with 
ADHD between 7 and 12 years of age. Fifteen of these children were between 10 
and 12 years of age. The time until the between peak minimum, and the time until 
the second peak were delayed and more variable in children compared to adults. 
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After a 20-mg dose of Methylphenidate, concentrations in children were 
approximately twice the concentrations observed in 18 to 35 year old adults. This 
higher exposure was almost completely due to the smaller body size and total 
volume of distribution in children, as apparent clearance normalized to body weight 
was independent of age. 
  Gender 
              There were no apparent gender differences in the pharmacokinetics  
between  male and female adults when Methylphenidate was administered. 
  Renal Insufficiency 
              Renal insufficiency was expected to have minimal effect on the 
pharmacokinetics of methylphenidate since less than 1% of a radio labeled dose was 
excreted in the urine as unchanged compound. 
Hepatic Insufficiency 
                  Hepatic insufficiency was expected to have minimal effect on the 
pharmacokinetics of methylphenidate since it was metabolized primarily to ritalinic 
acid by nonmicrosomal hydrolytic esterases that are widely distributed throughout 
the body. 
 
Drug-Drug Interactions 
      Carbamazepine- Carbamazepine may decrease the effect of methylphendiate.  
      Cyclosporine-Methylphenidate increases the effect and toxicity of cyclosporine 
      Guanethidine- Methylphenidate may decrease the effect of guanethidine.  
      Isocarboxazid- Possible hypertensive crisis with this combination. 
      Phenelzine -Possible hypertensive crisis with this combination . 
Precautions: 
                      Methylphenidate has high potential for abuse due to its 
pharmacological similarity to Cocaine and Amphetamines. 
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Excipients profile 
1.Sugar spheres
49
 
      Nonproprietary names 
                Sugar Spheres USPNF, EP,BP 
      Synonyms 
                Non-pareil, non-pareil seeds, Nu-Core, Nu-Pareil PG, sacchari sphaerae, 
sugar seeds, Suglets. 
       Category  
              Tablet and capsule diluent. 
       Applications 
                Sugar spheres are mainly used as inert cores in capsule and tablet 
formulations, particularly multiparticulate sustained-release formulations.  
      Description 
                  White free flowing granule 
       Bulk Density 
                 1.57–1.59 g/cm3 for Suglets less than 500 mm in size, 
                   1.55–1.58 g/cm3 for Suglets more than 500 mm in size. 
       Loss on Drying: 4% 
       Solubility 
                    solubility in water varies according to the sucrose-to-starch ratio. The 
sucrose component was freely soluble in water, whereas the starch component was 
practically insoluble in cold water. 
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        Stability and storage 
                   Sugar spheres are stable when stored in a well-closed container in a 
cool, dry place. 
 
 
2 Poly ethylene glycol- 6000 
50
 
      Nonproprietary Names  
                                          BP: Macrogol 
                                         JP: Macrogol 6000 
                                         Ph. Eur: Macrogols 
                                         USPNF: Polyethylene glycol 
       Synonyms 
                        Carbowax, Carbowax Sentry, Lipoxol, Lutrol E, PEG, PluriolE, 
polyoxyethylene glycol. 
      Chemical Name 
                       a-Hydro-o-hydroxy poly (oxy-1,2-ethanediyl) 
      Empirical Formula  
                       HOCH2 (CH2OCH2)m CH2OH where “m” represents the average 
number of oxy ethylene groups. 
       Functional Category 
                     Ointment base, plasticizer, solvent, suppository base, tablet and capsule 
lubricant. 
      Applications 
                    Plasticizer, Tablet Binder, Suspending agent, Emulsifying agent, 
Suppository base, Disintegrant.Mol wt above 6000 can be used as Lubricants. 
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   Solubility 
                    Soluble in acetone, dichloromethane, ethanol (95%), and methanol. 
They are slightly soluble in aliphatic hydrocarbons and ether. 
   Description 
         Solid grades (PEG>1000) are white or off-white in color, and range in 
consistency from pastes to waxy flakes. They have a faint, sweet odor. Grades of 
PEG 6000 and above are available as free flowing milled powders. 
Density 
         1.15–1.21 g/cm3 at 250C  
Stability and Storage Conditions 
                 Polyethylene glycols are chemically stable in air and in solution, 
Polyethylene glycols do not support microbial growth, and they do not become 
rancid. Polyethylene glycols should be stored in well-closed containers in a cool, dry 
place. Stainless steel, aluminum, glass, or lined steel containers are preferred for the 
storage of liquid grades. 
 Incompatibilities 
                  Incompatible with some coloring agents. 
 Safety 
                    Polyethylene glycols were widely used in a variety of pharmaceutical 
formulations. Generally, they are regarded as nontoxic and nonirritant materials. 
                     PEG 6000 was a solid grade. It is used as plasticizer. When it was used 
along with coating material it avoids rupture of film. Hence PEG 6000 was selected 
as plasticizer.  
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3.Poly vinyl pyrrolidone (PVP K30)
51
 
Nonproprietary Names         BP     : Povidone 
                                               JP      : Povidone 
                                              Ph Eur: Povidone 
                                             USP     : Povidone 
Synonyms 
                    E1201, Kollidon, Plasdone, poly[1-(2-oxo-1-pyrrolidinyl)ethylene], poly 
vidone,   polyvinyl pyrrolidone, PVP, 1-vinyl-2-pyrrolidinone polymer. 
Chemical Name 
                   1-Ethenyl-2-pyrrolidinone homo polymer 
Empirical formula 
                        (C6H9NO)n 
Molecular Weight: 50 000 
Structural formula: 
 
Figure:19 Structural Formula of PVP K30 
Category:   
                 Disintegrant, dissolution enhancer, suspending agent, tablet binder. 
Description: 
                  Occurs as a fine, white to creamy-white colored, odorless or almost 
odorless, spheres. 
pH: 
              3.0–7.0 (5% w/v aqueous solution). 
Density (bulk): 
               0.29–0.39 g/cm3 
Density (tapped): 
                 0.39–0.54 g/cm3  
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Density (true): 
               1.180 g/cm
3 
Melting point: 
                150
0
C. 
 
Applications:  
 
Use Concentration (%) 
Carrier for drugs 10-25% 
 
Carrier for drugs Up to 5% 
 
Dispersing agent 
 
Up to 5% 
Eye drops 2–10% 
 
Suspending agent Up to 5% 
 
Tablet binder, Tablet Diluent, or Coating 
agent 
0.5-5% 
 
Table:6 Applications of PVP K30 
 
Solubility: 
              Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and 
water, practically insoluble in ether, hydrocarbons, and mineral oil.  
 
Stability and storage: 
               Darkens to some extent on heating at 150°C, with a reduction in aqueous 
solubility. It should be stored in an airtight container in a cool, dry place. 
 
Incompatibilities: 
                Compatible in solution with a wide range of inorganic salts, natural and 
synthetic resins, and other chemicals. 
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4.Ethyl cellulose N-45
52
 
   Nonproprietary Names: 
                                               BP: Ethylcellulose 
                                          PhEur: Ethylcellulose 
                                       USP-NF: Ethylcellulose 
 Synonyms:  
          Aquacoat ECD, Aqualon, Ashacel, E462, Ethocel, ethylcellulosum, Surelease. 
Chemical Name: 
          Cellulose ethyl ether  
Empirical Formula:  
            C12H23O6 (C12H22O5)n C12H23O5 
Molecular Weight:  
             n can vary to provide a wide variety of molecular weights. 
Solution viscosity: 
             EC N-45  :41 to 49  
Structural formula: 
 
 
                                   Figure :20 Structural Formula of Ethyl Cellulose 
Category: 
           Coating agent, Flavoring agent, Tablet Binder, Tablet Filler, Viscosity 
increasing agent. 
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Applications:       
                             Table:7 Applications of Ethyl Cellulose 
Use Concentration (%) 
Microencapsulation 10.0–20.0 
Controlled-release  tablet           
coating 
2.0–20.0 
Tablet coating 1.0–3.0 
Tablet granulation 1.0–3.0 
 
Description:  
          Ethyl cellulose was a tasteless, free-flowing, white to light tan-colored 
powder. 
Density (bulk): 
            0.4 g/cm3 
Solubility: 
            Ethyl cellulose was practically insoluble in glycerin, propylene glycol, and 
water.Ethyl cellulose that contains less than 46.5% of ethoxyl groups was freely 
soluble in chloroform, methyl acetate, and tetrahydrofuran, and in mixtures of 
aromatic hydrocarbons with ethanol (95%). Ethyl cellulose that contains not less 
than 46.5% of ethoxyl groups was freely soluble in chloroform, ethanol (95%), ethyl 
acetate, methanol, and toluene.  
Stability and storage: 
              Ethyl cellulose was a stable, slightly hygroscopic material. Ethyl cellulose 
was subjected to oxidative degradation in the presence of sunlight or UV light at 
elevated temperatures. Ethyl cellulose should be stored at a temperature not 
exceeding 328C (908F) in a dry area away from all sources of heat. It should not be 
stored next to peroxides or other oxidizing agents. 
                Ethyl cellulose was used as modified release polymer. It acts as matrix 
and retards drug release from the dosageform. Drug release mechanisam was 
modified when Ethyl Cellulose was used. 2.0-20% of ethyl cellulose can use as 
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controlled release polymer. Hence Ethyl Cellulose was selected as controlled release 
polymer. 
 
5.Isopropyl alcohol
53
 
    Synonyms 
               Diethyl cardinal, IPA, isopropanol, petrohol 2-propanol. 
     Empirical formula 
                C3H8O  
      Molecular weight 
                 60.1  
         Description 
                     It was a clear color less, mobile, volatile, flamable, liquid with a  
characteristic spirituous odour resembling that of a mixture of ethanol and acetone; it 
has a slight bitter taste. 
         Functional categories 
                      Disinfectant, solvent. 
        Solubility  
                   Miscible with benzene, chloroform, ethanol (95%), ether, and water. 
        Melting point 
                     88.5
 o 
C. 
        Flash point 
                    11.7
 o 
C (closed cup),10
 o 
C (open cup). 
        Moisture content 
                    0.1-13%w/w commercial grades-13%w/w. 
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        Stability and storage conditions 
                    Stored in well-closed container in a cool and dry place. 
        Applications 
                    Used in lotions, used as a solvent  both for  tablet film coating and 
granulation. Topical disinfectant. 
       
6. Anhydrous sodium acetate
54
 
     Nonproprietary Names 
                                         BP: Sodium Acetate Trihydrate 
                                         JP: Sodium Acetate Hydrate 
                                         PhEur: Sodium Acetate Trihydrates 
                                         USP: Sodium Acetate 
       Synonyms 
                  Acetic acid, sodium salt, E262, natrii acetas trihydricus, sodium 
ethanoate. 
       Chemical Name 
                   Sodium acetate anhydrous 
        Empirical Formula 
                     C2H3NaO2   
        Molecular Weight 
                          82.0 
    Category 
              Antimicrobial preservative, buffering agent, flavoring agent, stabilizing 
agent. 
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 Applications 
                    Sodium acetate is used as part of a buffer system when combined 
with acetic acid in various intramuscular, intravenous, topical, ophthalmic, nasal, 
oral, otic, and subcutaneous formulations. 
  Stability and Storage Conditions 
                Sodium acetate should be stored in airtight containers. 
  Incompatibilities 
                   Sodium acetate reacts with acidic and basic    components. It will 
react violently with fluorine, potassium nitrate, and diketone. 
 
7. Acetic acid 
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Nonproprietary Names 
                                       BP: Glacial Acetic Acid 
                                       JP: Glacial Acetic Acid 
                                       PhEur: Acetic Acid, Glacial 
                                       USP: Glacial Acetic Acid 
 Synonyms 
            Acidum aceticum glaciale, E260, ethanoic acid, ethylic acid, methane 
carboxylic acid, vinegar acid. 
  Chemical Name 
                     Ethanolic acid  
   Empirical Formula 
                              C2H4O2  
   Molecular Weight 
                                  60.05 
    Functional Category 
                          Acidifying agent. 
     Applications  
                       Glacial and diluted acetic acid solutions are widely used as 
acidifying agents in a variety of pharmaceutical formulations and food 
preparations. Acetic acid is used in pharmaceutical products as a buffer system 
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when combined with an acetate salt such as sodium acetate. Acetic acid is also 
claimed to have some Antibacterial and Antifungal properties. 
      Description 
                     Glacial acetic acid occurs as a crystalline mass or a clear, colorless 
volatile solution with a pungent odor.  
      Solubility 
                      Miscible with ethanol, ether, glycerin, water, and other fixed and 
volatile oils.  
      Stability and Storage Conditions 
                     Acetic acid should be stored in an airtight container in a cool, dry 
place. 
      Incompatibilities 
                      Acetic acid reacts with alkaline substances. 
 
8.Talc
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    Nonproprietary Name 
    BP-Purified Talc 
   JP-Talc 
   PhEur-Talc 
                                    USP-Talc 
Synonyms 
       Altalc; E553b; hydrous magnesium calcium silicate; hydrous magnesium 
silicate; Luzenac Pharma; magnesium hydrogen metasilicate; MagsilOsmanthus; 
Magsil Star; powdered talc;purified French chalk; Purtalc; soapstone; steatite; 
Superiore. 
 Chemical Name  
                    Talc 
Empirical Formula  
                      Mg6(Si2O5)4(OH)4. 
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Functional Category   
                Anti caking agent; Glidant; Tablet and Capsule Diluent; Tablet and 
Capsule Lubricant. 
Applications in Pharmaceutical Formulation or Technology : 
                Talc was once widely used in oral solid dosage formulations as a 
Lubricant and Diluent, although today it was less commonly used. Talc was also 
used as a Lubricant in tablet formulations in a Novel powder coating for 
Extended-Release pellets;and as an adsorbant. 
Description 
                Talc is a very fine, white to grayish-white, odorless, impalpable, 
unctuous, crystalline powder. 
 
Moisture content  
               Talc absorbs insignificant amounts of water at 
258
0
C and relative humidities up to about 90%. 
 
Storage Conditions 
              Talc should be stored in a well-closed container in a cool, dry 
place. 
 
Incompatibilities 
               Incompatible with quaternary ammonium compounds. 
 
 
9.Hypromellose
57
 
 
Nonproprietary Names 
                              BP: Hypromellose 
                              JP: Hypromellose 
                              PhEur: Hypromellose 
                              USP: Hypromellose 
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Synonyms 
             Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; 
 hypromellosum; Methocel; methylcellulose propylene glycol ether; 
 methyl hydroxypropylcellulose; Metolose; MHPC; Pharmacoat; 
Tylopur; Tylose MO. 
Chemical Name 
              Cellulose hydroxypropyl methyl ether  
Molecular Weight 
              10 000–1 500 000  
Functional Category 
                 Bioadhesive material; coating agent; controlled-release agent; 
dispersing agent; dissolution enhancer; emulsion stabilizer; extended-release 
agent; film-forming agent; modified-release agent; mucoadhesive; release-
modifying agent; solubilizing agent; suspending agent; sustained-release agent; 
tablet binder; thickening agent; viscosity-increasing agent. 
  
Applications in Pharmaceutical Formulation 
             Hypromellose is widely used in Oral, Ophthalmic, Nasal and Topical 
pharmaceutical formulations.In oral products, Hypromellose is primarily used as 
a Tablet Binder(1) in Film-coating(2–7) and as a matrix for use in Extended 
Release tablet formulations(8–12) Concentrations between 2% and 5% w/w may 
be used as a Binder in either Wet- or Dry-granulation processes.  
 
Description: 
              Hypromellose is an odorless and tasteless, white or creamy-white 
fibrous or granular powder. 
 
Stability and Storage Conditions: 
               Hypromellose powder is a stable material, although it is hygroscopic 
after drying. should be stored in a well-closed container, in a cool, dry place. 
 
Incompatibilities: 
             Hypromellose is incompatible with some oxidizing agents. 
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                                                    Plan of the Work 
 
The plan of study of the work is as follows. 
 Collection of Literature review. 
 Preformulation study of drug and excipients. 
 Compatibility study of drug with excipients. 
 Formulation setup. 
 Formulation of Controlled release Methylphenidate Hydrochloride pellets. 
 Filling of drug pellets into capsules No.1 
 Evaluation tests 
                Evaluation tests for drug loaded pellets: 
 Physical Description 
 Sieve Analysis 
 Bulk Density  
 Moisture content 
 Compressibility Index  
 Hausner ratio 
                Evaluation tests for capsules containing pellets: 
  
 Weight variation test 
 Content uniformity 
 Lock length 
 In-Vitro drug release profile 
     Stability studies. 
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MATERIALS AND METHODS 
 
4.1List of Materials: 
 
 
INGREDIENTS 
 
MANUFACTURER 
Methylphenidate Hydrochloride Sun Pharma,Mumbai. 
Sugar Spheres(#20-#25) 
Arun Pharma,Cambodia. 
Ethyl Cellulose N-45 
Colorcon,North America. 
PVP k30 
ISP Pharma,California. 
PEG6000 
Clarient,Columbia. 
HPMC E5 
Shin-Etsu,Japan. 
Talc 
Luzenac pharma,Europe. 
IPA 
Rf  Cl  Ltd,New Delhi. 
Purified water 
RA Chem,Hyderabad. 
 
Table 8: List of Materials 
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4.2List of eqiupments: 
 
 
EQUIPMENT MANUFACTURER 
Weighing balance Sartorius (LA120S, TE 
2145),Bangalore. 
 
 
Essae 
Weighing balance Essae DS-852,Bangalore. 
Mechanical stirrer REMI Electrotechnik 
RQ1291D,Mumbai. 
Tapped density apparatus Electro lab (ETD-
1020),Mumbai. 
Fluidised Bed Processor 
Pharmatech UFBM-
3,Maharashtra. 
Dissolution test system Electrolab ED2AL,Mumbai. 
UV Spectrophotometer  Shimadzu UV2450,Singapore. 
pH meter Eutech Cyberscan-100,USA. 
Automatic capsule filling machine Rimek formulations,Gujarat. 
HPLC Shimadzu LC-2010C,Singapore. 
FTIR Shimadzu,Singapore. 
 
Table 9: List of equipments 
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4.3. Methodology 
4.3.1. Preformulation studies 
58 
                  Preformulation study is an investigation of physical and chemical 
properties of a drug substance alone and when combined with excipients. It is the 
first step in the rationale development of dosage form. 
Objective and  Scope 
                   The overall objective of Preformulation study is to generate 
information useful to the formulation development for a stable and bioavailable 
dosage forms. 
The use of Preformulation parameters is to maximize the chances in formulating 
an acceptable, safe, efficient and stable product.
59
 
 
Characterization of Methylphenidate Hydrochloride 
Physical Appearance 
                      The appearance of the API is done by visual observation. Results of 
physical appearance are mentioned in 5.1.1.
60
 
DSC study
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                The study of phase transitions between the various solid states is 
important to the pharmaceutical and other industries.Measurements using  DSC 
have become a popular way of studying the thermal reactions of solids. 
Differential scanning calorimetry (DSC) monitors heat effects associated with 
phase transitions and chemical reactions as a function of temperature and is a 
very informative method in physical characterization of a compound. In  DSC, 
the difference in heat flow to the sample and a reference at the same 
temperature, is recorded as a function of temperature. The reference is an inert 
material such as alumina, or just an empty aluminum pan. The temperature of 
both the sample and reference are increased at a constant rate. Since the DSC is 
at constant pressure, heat flow is equivalent to enthalpy changes: 
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    (dq/dt)p = dH/dt 
 
 
Here dH/dt is the heat flow measured in mcal sec. The heat flow difference 
between the sample and the reference is: 
 
 
 ΔdH/dt = (dH/dt)sample – (dH/dt)reference 
 
 
                              The endothermic transition upon heating from a crystalline 
solid to the liquid state. This process is also called fusion. The enthalpy of 
melting is the heat energy required for melting, i.e. for breaking down the 
crystalline lattice. This is calculated by integrating the area of the DSC peak on 
a time basis. A sharp well defined melting peak corresponds to at well-defined 
crystal structure. Changes in melting temperature and energy gives information 
about, for instance, content of amorphous material. Thus, the melting 
endotherm can be used for determination of purity of the sample.The DSC study 
of Methylphenidate Hydrochloride was carried out for the determination of 
melting point.Results was mentioned in Fig:21 
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Solubility studies 
62 
                            The solubility of drug is an important physicochemical property 
because it affects the bioavailability of the drug, the rate of drug release into the 
dissolution medium, and consequently the therapeutic efficacy of the 
pharmaceutical product. The solubility of a material is usually determined by 
the equilibrium solubility method, which employs a saturated solution of the 
material, obtained by stirring an excess of material in the solvent for a 
prolonged period until equilibrium is achieved. Results of solubility studies are 
mentioned in 5.1.1. 
 4.3.2 Physical drug excipients compatibility studies
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                            Compatibility studies were carried out to study the possible 
interactions between Methylphenidate Hydrochloride and other inactive 
ingredients. 
Procedure:  
               The compatibility studies were carried out by taking a mixture of drug 
and excipients. A part of mixture can be exposed to different storage conditions 
like 40
o
C±2
o
C / 75% RH ±5%  and control samples were to be kept  at      2-8 
o
C. 
They were tested with respect to their physical and chemical aspects. These 
samples were collected at regular intervals and subjected to FT-IR. Results of 
drug and excipients compatibility studies are mentioned in Table 12. 
S.No.    Storage Condition Samples packed  in Sampling Periods in 
Months 
1 
 
 
Accelerated 
40 
o
C±2
  o
C /75% RH ±5%  
3 Double polythene 
bags 
1M,2M,3M 
2 Refrigeration   2-8
o
C 
1 Double polythene 
bag + 1 glass vessel 
1M,2M,3M 
 
Table :10 Conditions for compatibility studies 
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4.3.3. Analytical Method Development 
a. Calibration curve of  Methylphenidate Hydrochloride in pH 0.01N HCl 
acetate buffer 
                       The analytical method development for Methylphenidate 
hydrochloride was performed for the determination of absorption maxima of the 
drug and quantification of pellets prior proceeding for the experiment. 
Methylphenidate hydrochloride is scanned in the respective medium of pH 0.01N 
acetate buffer for its absorption maxima and was found that Methylphenidate 
hydrochloride exhibited maximum absorption at 210.0 nm. 
 100mg of Methylphenidate hydrochloride was added to 100ml of 0.01N 
pH acetate buffer. 
 10 ml was taken from the above solution and diluted to 100ml with the 
same pH 1.2 (0.01N HCl) acetate buffer. This is referred as primary stock 
solution. 
 From the primary stock solution, serial dilutions wre performed to give a 
concentrations of 10, 20, 40, 60,80,100mcg/ml. 
 Solutions were analysed by UV-Spectrophotometer at a λ max of 210nm. 
 
  The absorbances of respective solutions were determined at 210 nm 
against (0.01N Hcl) buffer as the blank. The experiment was repeated six 
times in the same medium and a calibration curve was determined from 
the mean value. From this data, the standard curve of Methylphenidate 
was obtained by plotting absorbance on Y-axis against concentration on 
X-axis. Results of standard graph are mentioned in  Table 13& Fig 28. 
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b.   Calibration Curve of Methylphenidate Hydrochloride in 6.8 pH 
Phosphate Buffer 
 100mg of Methylphenidate hydrochloride was added to 100ml of 6.8pH 
phosphate buffer. 
 10 ml was taken from the above solution and diluted to 100ml with the 
same phosphate buffer. This was referred as primary stock solution. 
 From the primary stock solution, serial dilutions were performed to give a 
concentrations of 10, 20, 40,60,80,100 mcg/ml 
 Solutions were analysed by UV-Spectrophotometer at a λ max of 210nm. 
 The absorbances of respective solutions were determined at 210 nm 
against 6.8pH buffer as the blank. The experiment was repeated six times 
in the same medium and a calibration curve was determined from the 
mean value. From this data, the standard curve of Methylphenidate was 
obtained by plotting absorbance on Y-axis against concentration on X-
axis. Results of standard graph are mentioned in Table 14 & Fig 29. 
 
 
4.3.4 Method of manufacture 
 
Fluidized bed process: 
Raw material dispensing 
                  Accurately weighed quantities of raw materials and measured 
quantities of solvents were dispensed and transferred to manufacturing area. 
Drug solution preparation 
  PEG 6000 was dissolved in specific amount of water under stirred 
conditions. To this solution, PVP K30 was added and stirred under same 
conditions until a clear solution was obtained. Then Methylphenidate 
Hydrochloride was added under same stirred conditions until get a clear 
solution. 
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Drug Loading 
 Weighed quantity of sugar spheres were loaded onto FBP, and drug 
solution was coated onto sugar spheres. 
Coating Solution Preparation 
 Solution-1:Ethyl Cellulose N-45 was dissolved in specific quantity of IPA  
under stirred conditions. 
 Solution-2:PEG6000 and HPMC E5 was dissolved in specific quantity of 
water under stirred conditions. 
 Now the solution-2 was added to EC solution under stirring and was 
continued until a clear solution was obtained. Finally talc was added and 
stirred. 
Controlled Release Coating  
 The dried pellets were loaded onto FBP and coated with controlled release 
coating solution. 
 
Capsule Filling 
 The weight of pellets equivalent to 381mg Methylphenidate 
Hydrochloride were filled into hard gelatin capsules of size.1 by capsule 
filling machine.  
 
   Process Control Parameters 
Spray Gun:                  Umang 
Spray Type:                 Bottom spray 
Spray Rate:                  5ml/min 
Spray Pump RPM:       1-3 RPM 
Inlet Temperature:        50 °C 
Bed Temperature:         47 °C 
Outlet Temperature:      38 °C 
Air Pressure:                 0.7 Kg/cm
2 
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                                   4.3.5 Formulation development 
 
S.No. Ingredients 
Quantity(%w/w) 
F 1 F 2 F 3 F 4 F 5 F 6 F 7 F 7 
1 
Sugar Spheres(#20-
#25) 
83.85 83.47 83.1 82.8 82.9 82.33 82.86 82.86 
2 
Methylphenidate 
Hydrochloride 
  10.5 10.5 10.5 10.5 10.5 10.5 10.5 10.5 
3 PVP K30 3 3 3 3 3 3 3 3 
4 PEG 6000 0.5 0.6 0.7 0.8 0.8 0.8 0.5 0.5 
5 Purified Water Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
 
Controlled release coating 
6 Ethyl cellulose N-45 1.5 1.75 2.0 2.0 2.0 2.5 2.3 2.3 
7 HPMC E5 0 0 0 0.2 0.1 0.125 0.115 0.115 
8 PEG 6000 0.15 0.175 0.2 0.20 0.2 0.25 0.23 0.23 
9 IPA Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
10 Purified Water Q.S Q.S Q.S Q.S Q.S Q.S Q.S Q.S 
11 Talc 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
 
Table:11 Comparison of Trial Batches 
 
.                                          
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 4.3.6 Evaluation of pellets
64
 
Evaluation tests for drug loaded pellets: 
a.Physical Description 
b.Sieve Analysis 
c.Bulk Density and Tap density 
d.Moisture content 
e.Compressibility Index  
f.Hausner ratio 
Evaluation tests for capsules containing pellets: 
  
      a. Weight variation test 
      b.  Content uniformity 
      c. Lock length 
     d.  In-Vitro drug release profile 
 
Evaluation tests for Drug Loaded Methylphenidate pellets:  
a.Physical description: 
                  0.5g of pellets were transferred into a dry Petri dish or dispensed on a 
white card. Observed the content visually. Results of physical description are 
mentioned in page 92. 
 
b. Sieve analysis: 
                   The particle size of the pellets after drug loading was evaluated by 
mechanical sieving using a series of sieves with aperture size 1, 0.85, 0.71, 
0.60mm. A sample load of 100g was placed on the sieve and shaken by 
mechanical shaker. The weight of pellets retained on each sieve were determined 
and mean particle size have been determined. Results of sieve analysis are 
mentioned in page 92. 
 
c. Bulk density and Tap density: 
                   Bulk density was determined by USP method-I. 20g of pellets was 
taken and poured into a measuring cylinder. Bulk volume of pellets was noted. 
                 Bulk density= Mass of pellets/ Bulk Volume. 
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                  Tap Density is determined with tap density tester, by placing a 
graduated cylinder containing a known mass of pellets in it, which is then 
operated for a fixed number of taps (500). Results of Bulk density and Tap 
density are mentioned in Table 15. 
                          Tapped density= Mass of pellets/ Tapped Volume.  
 
d. Water content by KF Titration: 
                   30ml of methanol was taken in a clean, dried Karl Fischer titration flask 
and titrated with KF reagent until the end point to neutralize the free water. 
Methylphenidate pellets were powderd finely. Accurately weighed quantity of 
0.5gm of sample is transferred  to the titration flask and dissolved by stirring and 
titrate with KF reagent to the end point and percentage water content was calculated 
by following formula. Results of water content are mentioned in Table 16. 
                         % Water Content = V×F×100/W×100 
Where,     
V = Volume of KF reagent consumed by sample 
F = Factor for KF reagent 
W = Weight of sample in grams. 
 
e. Compressibility index : 
                       It is an important measure that can be obtained from the bulk and 
tapped densities. In theory, the less compressible a material the flow able it is. A 
material having values of less than 20-30% is defined as the free flowing 
material.  
CI=TBD-LBD/TBDx100 
Where 
TBD=Tapped bulk density   LBD=Loose bulk density. 
 
f. Hausner’s ratio: 
               It indicates the flow properties of powder and is measured by the ratio 
of tapped density to bulk density. Results of Hausner’s ratio are mentioned in 
table 15.       
Hausner’s ratio=Tapped density/Bulk density 
 77 
 
                       Evaluation tests for capsules containing pellets
 
a. Weight variation test
 
                 20 intact capsules were selected randomly and weighed and average 
weight is calculated. Individual weight of each capsule is determined. According 
to USP, none of the individual capsule weight should be less than 90% and more 
than 110% of the average weight. Results of weight variation test are mentioned 
in Table 17. 
 
b. Lock length 
                   The lock length can be determined by vernier callipers. The empty 
capsule cap and body were measured individually to know the lock length of the 
capsule. Results of lock length are mentioned in Page 94. 
 
c. Content uniformity by HPLC 
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                   According to USP, 30 intact capsules were selected, of which 10 are 
assayed. 9 of 10 capsules should be within the potency range of 85%-115%. The 
potency of 10th
 
capsule should not exceed the range of 75-125%. Results of 
Content uniformity are mentioned in Table 17. 
 
Reagents: 
Anhydrous sodium acetate: A.R Grade 
Acetic acid:   A.R Grade 
Acetonitrile:  HPLC Grade 
Methanol:     HPLC Grade 
 
Preparation of buffer solution 
                 Acetate buffer-Accurately weighed and transferred about 1.64 g of 
anhydrous sodium acetate into a beaker containing 900 ml of water and mixed. 
Adjusted pH with acetic acid to 4.0, diluted with water to 1000 ml, and mixed.  
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Preparation of mobile phase 
                      Filtered and degassed mixture of Methanol, Acetonitrile, 
and Acetate buffer (4:3:3) was prepared. 
 
Preparation of standard solution 
                      Accurately weighed and transferred 20mg of Methylphenidate 
Hydrochloride working standard into a 100ml of volumetric flask, added 70ml of 
Mobile phase and sonicated, dissolved, diluted to volume with Mobile phase and 
mixed. Transferred 10ml of this solution to 20ml volumetric flask and diluted to 
volume with Mobile phase. Filtered the solution through 0.45 Nylon filter paper.  
 
Preparation of Sample Solution 
                         Accurately weighed and transferred the pellets equivalent to about 
20mg of Methylphenidate Hydrochloride into a 100ml volumetric flask. Added 
about 70ml of mobile phase and sonicated for 15min with intermittent shaking. 
Diluted to volume with mobile phase. Transferred 10ml of this solution into a 
20ml volumetric flask and diluted to the volume with mobile phase. 
 
Chromatographic Conditions 
Column                         : Kromosil 60, CN 250×4.6 mm, 5µm or equivalent. 
Flow Rate                      : 1.5 ml/min 
Wave Length                 : 210 nm 
Column Temperature     : 25°C 
Injection Volume           : 50µl 
Run Time                      : 10minutes. 
 
 
System Suitability 
                   The percentage relative standard deviation for six replicate injection 
of standard solution is not more than 2.0 
 
 
 
 79 
 
 
Procedure 
                Separately injected equal volumes (about 50 µL) of the Standard 
preparation and sample solution into the chromatograph, recorded the 
chromatograms, and measured the responses for the major peaks. Calculated the 
quantity, in mg, of Methylphenidate hydrochloride in the portion of pellets  taken 
by the formula. 
 
                             AT      WS       10     100      20      p           
%Drug Content = ---x-----x-----x--------x-----x-------x------100 
                                As      100      20      WT          10   100    
 
 
                                             % of Methylphenidate Hydrochloride 
% of labeled amount =--------------------------------------------------×100 
                                                     Label claim 
Where, 
AT      = Area count of Methylphenidate Hydrochloride Peak in sample solution. 
As = Average area of Methylphenidate Hydrochloride peak in sample solution.  
WS = Weight of Methylphenidate working standard taken in mg. 
WT = Weight of the sample taken in mg. 
P = Purity of Methylphenidate working standard used. 
 
d. In vitro dissolution by HPLC 
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                   In vitro drug release studies were carried out using an USP type I 
dissolution test apparatus at 75rpm for 2 hrs in 0.01N Hcl  acetate buffer (500 ml) 
maintained at 37°C ± 0.5°C and 10 ml of sample was withdrawn and analyzed. 
                     Then, the dissolution medium was replaced with pH 6.8 phosphate 
buffer (500 ml) and tested for drug release for 8 hrs at same temperature and 
same rotation speed. At all the time points of 0.5,1,3,6,8 and 10,each 10 ml of the 
samples were withdrawn, and analyzed. The results of invitro dissolution was 
mentioned in table18. 
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Preparation of Standard: 
                       Transferred about 20mg of Methylphenidate Hydrochloride, 
accurately weighed, to a 50ml volumetric flask added 20ml of methanol, 
sonicated to dissolve and diluted with methanol to volume and mix. Transferred 
5.0ml of this solution to a 50ml volumetric flask, diluted with medium to the 
volume and mixed. Filtered the solution through Nylon filter paper. 
 
Sample Preparation:  
                         The parameters of dissolution apparatus were set as mentioned 
above and a capsule is placed in each dissolution vessel containing pellets 
equivalent to 380.95mg Methylphenidate Hydrochloride and the dissolution 
apparatus was operated. 10ml of the sample solution was withdrawn from each 
vessel at the end of the time point.10 ml of withdrawn sample is transferred to 
25ml volumetric flask and made up to the volume with dissolution medium. 
 
Procedure: 
                 Separately injected 50µl of standard solution (six injections) and 
sample solution into the chromatographic system. Recorded the chromatograms 
and measured the peak responses. 
 
Calculation: 
                  % labeled amount of Methylphenidate dissolved 
 
        AT      WS        5       500                   P 
   =   -------x-------x------x--------x----------------------- x 100 
       AS       50      50       WT       label Claim in % 
where, 
AT = Area of Methylphenidate Hydrochloride in sample solution 
AS = Area of Methylphenidate Hydrochloride in standard solution 
WS = Weight of Methylphenidate in working standard(mg) 
WT =  Weight of sample taken (mg) 
P = Purity of Methylphenidate Hydrochloride  working standard taken in mg. 
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               4.3.7. DISSOLUTION PROFILE COMPARISON USING         
                      SIMILARITY AND DISSIMILARITY FACTORS 
                    f1=Dissimilarity factor 
                    f2=Similarity factor 
A dissolution profile can characterize the product more precisely than a single 
point dissolution test. It helps to assure similarity in product performance and 
signals bioequivalence. The factor f1 is proportional to the average indifference 
between two profiles, where as factor f2 inversely proportional to the average 
squared indifference between two profiles. The factor f2 measures the closeness 
between two profiles, FDA has set a public standard of f2 value between 50-100 
to indicate similarity between two profiles. It was calculated by the following 
formulae. 
  
 f1= ΣD (1/ Σt) 100 
            f2 = 50 x ln{1/1+Σ (Rt-Tt)2} 
 
4.3.8 Stability studies 
                          Stability studies are an integral part of the drug development 
program and are one of the most important areas in the registration of 
pharmaceutical products. The purpose of stability testing is to provide evidence 
on how the quality of a drug substance or drug product varies with time under the 
influence of a variety of environmental factors such as temperature, humidity, 
light and enables recommended storage conditions, re-test periods and shelf  lives 
to be established.  
                              Stability assessment starts with studies on the substance to 
determine degradation products, degradation pathway. In these type of studies the 
pellets are stored in suitable containers and stability study is conducted as per 
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ICH guidelines. The product is analyzed at intervals for various parameters which 
may include assay of active ingredient, measurement of known degradation 
products, hardness, disintegration time, dissolution time, appearance, etc., 
Stability studies have been conducted at following conditions. Results of stability 
studies are mentioned in Table:12.. 
Storage conditions: 
              40 ºC ± 2 ºC /75%RH ± 5%, 25 ºC ± 2 ºC /60% RH ± 5%  
Packs:  
          Capsules containing pellets have been packed into blister packages. 
Period: 
            Initial, 1, 2 and 3 months. 
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                                    RESULTS AND DISCUSSIONS 
 
Preformulation studies 
5.1. API Characterization 
Appearance 
                  Methylphenidate Hydrochloride was a white to off white powder. 
Solubility 
                 The drug, Methylphenidate Hydrochloride was freely soluble in Water.  
DSC study 
              These studies shows the characteristic peaks of Methylphenidate 
Hydrochloride. 
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Figure:21 DSC graph 
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5.2 Drug excipient compatibility study 
Physical observation: 
                   Physical observation of sample was done every week for any color 
change or lumps formation and flow, storing at 40
o
C/ 75% RH 
 
S. 
No. 
Composition details 
Observations 
Storage condition / Duration 
Initial 
40
o
C/ 75%RH 
1Month 2Month 3Month 
1 
Methylphenidate  Hydrochloride 
alone 
White to off White 
powder NCC NCC NCC 
2 
Methylphenidate  Hydrochloride +  
Sugar spheres 
White to off White 
powder NCC NCC NCC 
3 
Methylphenidate  Hydrochloride +  
PEG 6000 
White to off White 
powder NCC NCC NCC 
4 
Methylphenidate  Hydrochloride +  
Polyvinyl pyrrolidone k30 
White to off White 
powder NCC NCC NCC 
5 
Methylphenidate   Hydrochloride+ 
Ethyl Cellulose N-45 
White to off White 
powder NCC NCC NCC 
6 
Methylphenidate   Hydrochloride+  
HPMC E5 
White to off White 
powder NCC NCC NCC 
 
Table :12 Drug excipients compatibility study 
NCC:No change in color 
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5.3.FT-IR Spectroscopy: 
                 Methylphenidate hydrochloride, PVP K30,  HPMC E5, are subjected 
to FT-IR spectroscopy. The FT-IR spectrums are interpreted and the functional 
groups C-H-2900cm
-1
, C=O- 1740cm
-1
(stretching) are identified in 
Methylphenidate hydrochloride. The functional groups C-N, C-O-1330cm
-
1
(stretching), N-H-1530cm
-1
(bending) are observed in PVPK30. The following 
functional groups are identified in  HPMC E5 polymers O-H-1330cm
-1
, C-H-
2960cm
-1
( stretching), C=C -  1680cm
-1
. From the spectrum of drug and excipient 
mixture, no interaction of drug and polymers have been observed. 
FTIR Spectra for Methylphenidate Hcl: 
 
Figure :22 FTIR Spectra of Methylphenidate Hydrochloride 
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FTIR Spectra for PEG-6000: 
 
Figure :23 FTIR Spectra of PEG-6000 
 
 
FTIR Spectra for PVPK-30: 
 
Figure :24 FTIR Spectra of PVPK-30 
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FTIR Spectra for Ethyl cellulose N-45: 
 
Figure:25 FTIR Spectra of Ethyl cellulose N-45 
 
 
 
 
 
FTIR Spectra for HPMC E5: 
 
 
 
 
 
Figure: 26 FTIR Spectra for HPMC E5 
 
 
 
 89 
 
 
 
FTIR Spectra for Physical mixture:                         
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Figure :27 FTIR Spectra of Physical mixture 
 
 
5.4Analytical Method Development: 
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a. Calibration Curve of  Methylphenidate Hydrochloride in pH 0.01N Hcl 
acetate buffer at λ max  210.0 nm 
Concentration 
(µg/mL) 
Absorbance 
10 0.113 
20 0.206 
40 0.457 
60 0.585 
80 0.751 
100 0.899 
 
Table:13 calibration of Methylphenidate Hcl in 0.01N Hcl acetate buffer 
 
 
 Figure:28 calibration curve of Methylphenidate Hcl in 0.01N Hcl acetate 
buffer 
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b.   Calibration Curve of Methylphenidate Hydrochloride in 6.8 pH 
Phosphate Buffer at λ max  210.0 nm: 
Concentration 
(µg/mL) 
Absorbance 
10 0.126 
20 0.218 
40 0.391 
60 0.611 
80 0.757 
100 0.921 
Table:14 calibration of Methylphenidate Hcl in 6.8pH phosphate 
buffer 
 
 
Figure:29 calibration curve of Methylphenidate Hcl in 6.8pH phosphate 
buffer 
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5.5.Evaluation of drug loaded pellets: 
Physical description: 
                0.5g of pellets were transferred into a dry petri dish or dispensed on a 
white card. The contents were observed visually. It was found that 
Methylphenidate Hydrochloride is a white to off white powder. 
 Sieve analysis: 
              All the Methylphenidate Hydrochloride formulations were tested for 
particle size by sieve analysis using mechanical sieve shaker. The size of pellets 
(841-1190µm) was found to be within the range of standard sieves. All the pellets 
are passed through sieve no.16 easily and retained on sieve no.20. 
                                       
 
S. No Formulation 
Bulk Density 
(gm/ml) 
Tap Density 
(gm/ml) 
Hausner ratio: 
 
1 F 1 0.66 ± 0.03 0.69 ± 0.02 1.04 
2 F 2 0.64 ± 0.03 0.67 ± 0.03 1.04 
3 F 3 0.66 ± 0.04 0.69 ± 0.04 1.04 
4 F 4 0.64 ± 0.04 0.67 ± 0.03 1.04 
5 F 5 0.65 ± 0.03 0.68 ± 0.02 1.04 
6 F 6 0.67 ± 0.04 0.71± 0.03 1.00 
7 F 7 0.66 ± 0.03 0.69 ± 0.05 1.04 
Table :15 Bulk density and Tap density 
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% Moisture content: It has been determined by KF Titration Method 
S. No Formulation % Moisture 
Content 
1 F 1  1.98 
2 F 2  1.95 
3 F 3 1.8 
4 F 4  1.73 
5 F 5 1.63 
6 F 6  1.42 
7 F 7             1.5 
Table :16  % Moisture content 
5.6. Evaluation of capsules containing pellets: 
       Weight variation & drug content: 
                     Capsules containing Methylphenidate formulations have shown the  
average weight & drug content uniformity in the range of  453.5-455.9 & 98.3%-
100.5%. 
S.No Formulation Average Weight 
(mg) 
%Drug Content 
1 F 1 453.5 ± 3.6 98.5 ± 0.2 
2 F 2 454.2 ± 5.8 99.7 ± 0.3 
3 F 3 454.7 ± 4.5 100.1 ± 0.2 
4 F 4 455.3 ± 3.5 99.5 ± 0.4 
5 F 5 454.6 ± 3.2 98.3 ± 0.3 
6 F 6 454.3 ± 4.5 99.7 ± 0.4  
 95 
 
7 F 7 455.9 ± 4.6 99.9 ± 0.2 
                                            Table : 17 Weight variation 
Weight variation profile: 
 
 
 
Figure:30 Weight variation profile of 7 formulations 
 
 
 
 
 Lock length: 
               Empty capsule cap length and width: 10.2mm, 6.58mm 
               Empty capsule body length and width: 16.82mm, 6.5mm 
               Filled capsule length and width: 19.22, 6.8mm 
               Lock length of the capsules containing pellets was found to be 7.8mm   
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Assay by HPLC 
 
 
HPLC Chromatogram for Blank 
 
Figure:31 HPLC Chromatogram for Blank 
 
 
HPLC Chromatogram for Standard 
 
Figure:32  HPLC Chromatogram for Standard 
 
 97 
 
 
HPLC Chromatogram for Optimised Formulation F7:  
 
 
Figure:33 HPLC Chromatogram for optimized formulation F7. 
 
 
 
 In-Vitro Drug release profile: 
Dissolution by HPLC: 
 
Stage:1 
Medium           : 0.01N Hcl acetate buffer 
Volume            :  500ml 
Apparatus       :  Basket(USP-I) 
 
RPM                :  75 
Time                :  2hours 
Temperature   :  37±0.5°C 
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Stage:2 
Medium           : 6.8pH phosphate buffer 
Volume            :  500ml 
Apparatus       :  Basket(USP-I) 
 
RPM                :  75                
Time                :  8 hours 
Temperature   : 37±0.5
0
 C     
                        
 
S.No 
 
Time 
  
(hrs) 
Cumulative  % Drug release 
Innovator 
Drug 
F1 F2 F3 F4 F5 F6 F7 F8 
1 0.5 27.4 36.3 32.8 28.8 40.8 35.8 22.5 24.1 24.2 
2 1 37.9 59.9 54.3 50.3 62.3 57.3 46.1 46.5 46.6 
3 3 56.3 74.6 71.2 67.3 79.5 76.1 65.3 65.6 65.1 
4 6 68.2 81.7 76.3 72.0 84.1 81.2 73.9 74.2 74.4 
5 8 84.6 85.3 80.2 76.9 88.4 84.9 81.2 83.5 83.7 
6 10 92.5 89.0 83.4 79.4 96.4 94.5 90.2 93.9 93.8 
                f2 Values 
          (Similarity  factor) 
43.4 48.7 51.2 39.5 44.4 50.6 61.1 61.1 
 
Table :18   Comparative dissolution data 
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Figure :34  In Vitro drug release profile of  F1. 
 
 
 
Figure :35  In Vitro drug release profile of  F2. 
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Figure :36 In Vitro drug release profile of  F3. 
 
 
 
Figure :37 In Vitro drug release profile of  F4. 
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             Figure :38  In Vitro drug release profile of  F5. 
                        
 
 
Figure :39  In Vitro drug release profile of  F6. 
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Figure :40 In Vitro drug release profile of  F7. 
 
 
 
Figure :41 Comparitive in vitro drug release profiles. 
 
 103 
 
Kinetic analysis of dissolution data: 
                       The release rate kinetic data for the F7 is shown in 
Table16. As shown in Figures 39-42, drug release data was best 
explained by zero order equation, as the plots showed the linearity (r
2
 = 
0.821). As the drug release was best fitted in zero order kinetics, 
indicating that the rate of drug release is concentration independent. 
 
Determination of release kinetics: 
 
Release kinetics R
2
 Intercept Slope 
Zero order 0.821 23.91 7.734 
First order 0.426 0.115 1.049 
Higuchi 0.956 28.051 7.801 
Korsmeyer peppas 0.818 -0.739 1.809 
 
Table :19Drug Release Kinetics of Batch (F7) capsules
 
* 
 r
2
 = Correlation coefficient 
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                   Figure :42 Zero Order Graph of Optimized 
Formulation(F7) 
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                  Figure :43  First Order Graph of Optimized 
Formulation(F7) 
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 Figure :44 Higuchi Plot of Optimized Formulation (F7 ). 
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 Figure :45 Korsmeyer-Peppas Graph of Optimized Formulation 
(F7). 
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Stability results: 
 
S.No Test 
Storage Condition 
40ºC ± 2ºC /75%RH ± 
5%RH 
Storage Condition 
25ºc ± 2ºC /60%RH  ± 
5% RH 
Initial 90 days Initial 90 days 
1 
Physical 
Appearance 
Off white Off white Off white Off white 
2 
% Moisture 
Content 
1.57 1.57 1.57 1.59 
3 
% Drug 
Content 
100.1 99.9 100.1 100 
4 
% Drug 
Release 
92.2 92.1 92.2 91.9 
 
Table :20  Stability results for selected formulation 
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Discussion 
                     Methylphenidate Hydrochloride controlled release capsules were 
prepared by using Fluidized Bed Process. Methylphenidate Hydrochloride was 
used to treat ADHD in children. Methylphenidate blocks dopamine uptake in 
central adrenergic neurons by blocking dopamine transport or carrier proteins. 
                     In preformulation study, API characterization was done. Drug and 
excipient blends were subjected to compatibility studies. From the FT-IR reports, 
it was found that there was no incompatibility between Methylphenidate 
Hydrochloride and other excipients. Physical compatibility was also tested by 
subjecting the blend to various storage conditions and it was found that the blend 
was stable.  
                     From DSC study ,it was concluded that for Methylphenidate 
Hydrochloride the onset of peak point was 218.5
0
C and peak appeared at the 
point of 221.34
0
C.So by  these values,  the melting point of Methylphenidate 
Hydrochloride was determined and the API used in the present study was stable. 
                    Evaluation of drug Loaded pellets was carried out. All the 
Methylphenidate Hydrochloride formulations were tested for particle size by 
sieve analysis using mechanical sieve shaker. The size of pellets was found to be 
within the range of standard sieves. All the pellets were passed through sieve 
no.16 easily and retained on sieve No.20. 
                   Bulk density of all formulations of Methylphenidate Hydrochloride 
pellets were found to be in the range of 0.64-0.67 gm/ml. Tap density of all 
formulations of Methylphenidate Hydrochloride pellets were found to be in the 
range of 0.68-0.71 gm/ml. 
                   The percentage of moisture content of all formulations of 
Methylphenidate Hydrochloride  pellets were found to be in the range of 1.42-
1.98%. 
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                      Evaluation of drug loaded pellets also carried out. Weight variation 
of all formulations of Methylphenidate Hydrochloride capsules were found to be 
in the range of 453.5 to 455.9 mg. Lock length of the capsules containing pellets 
was found to be 7.8mm 
                     Capsules containing Methylphenidate Hydrochloride formulations 
have shown the drug content uniformity in the range of 98.3%-100.1%. 
                    In vitro dissolution studies were carried out for all formulations. 
Drug release profile of F1 was less when compared with the reference 
product.More percent of drug was released in initial hours.By gradually 
increasing the concentration of Ethyl Cellulose N-45 and PEG6000 release rate 
was decreased.So a pore former HPMC E5 in concentration of 10% of        
Ethyl cellulose N-45 was introduced in the formulation F4.In this case drug 
release rate was good but release profile  does not match with the reference 
product. 
                      From F5 formulation,HPMC E5 in concentration of 5% of Ethyl 
Cellulose N-45 was used .The percent drug release was better but it does not 
matches with the reference product drug release profile.  
                       In F6 formulation,drug release profile was good but in last  four 
hours drug release rate was less when compared with the innovator drug release 
profile .So in F7 Ethyl Cellulose N-45 concentration was reduced to 2.3% .In 
this formulation,a maximum of 93.9%drug release was obtained at the 10
th
 hour 
and also drug release profile was matches with the reference product release 
profile.So the formulation  F7 batch was the optimized batch. 
                       Stability studies were conducted for F7 at two different         
storage conditions 25ºC ± 2ºC /60%RH  ± 5% , 40ºC ± 2ºC /75%RH ± 5% for a 
period of 90 days. The formulation was found to be stable with respect to 
physical appearance, percentage moisture content, percentage  drug content and 
percentage  drug release. 
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                                                          SUMMARY 
 
                        Controlled release Methylphenidate Hydrochloride capsules were 
developed in order to meet the required bio-availability and its in-vitro release 
pattern was studied. 
                               
                       The present work involves Preformulation studies, Physical drug 
excipient compatibility studies, Analytical method development, Manufacturing 
of capsules filled with drug loaded pellets and Evaluation procedures for pellets 
and capsules. 
 
                         In the preformulation studies, the API was studied for various 
parameters like physical description, Solubility and DSC studies. 
 
                         Drug excipients compatibility study was done every week for 
any color change or lumps formation and flow, storing at 40
o
C/ 75% RH, 2-8
o
C. 
It was found that no change in the color for all combinations.From the FT-IR 
reports, it was found that there is no incompatibility.Standard graph for the drug 
Methylphenidate Hydrochloride was plotted and the results were found to be 
accurate and precise. 
 
                         In this study Methylphenidate Hydrochloride extended release 
pellets (40 mg) were prepared by Fluidized Bed Processing. The pellets were 
evaluated for various parameters. Various formulations were developed by 
changing the strengtht of Ethyl cellulose N-45.  
 
                       All the Methylphenidate Hydrochloride formulations were tested 
for particle size by sieve analysis. The size of pellets (841-1190µm) was found 
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to be within the range of standard sieves. Bulk density of all formulations of 
Methylphenidate Hydrochloride pellets were found to be in the range of 0.64-
0.67 gm/ml. Tap density of all formulations of Methylphenidate pellets were 
found to be in the range of 0.68-0.71 gm/ml. The moisture content of all the 
formulations was found to be within the range of 1.20 – 1.98 %. The 
compressibility of all formulations was found to be within the range of 14.81-
20.45. 
 
                     Capsules filled with pellets were evaluated for various parameters. 
The weight variation was found to be within the limits. Lock length of the 
capsules containing pellets was found to be 7.8mm. Capsules containing 
Methylphenidate Hydrochloride formulations have shown the drug content 
uniformity in the range of 98.3%-100.5%.  
 
                       Various formulations were developed by changing the strength of 
sugar spheres, Ethyl cellulose N-45 ,PEG6000 and HPMC E5. All the 
formulations showed better results with respect to physical appearance and 
particle size etc, but the drug release profiles were varying. 
 
                        By increasing the concentration of Ethyl Cellulose N-45 the drug 
release profile was varying with other formulation. Formulations were done by 
increasing the concentration of Ethyl Cellulose N-45. At the strength of 2% w/w 
the drug release was below the reference drug release profile, at 2.5%  w/w (F6) 
the profile was having good similarity but at optimum concentration of 2.3 % 
w/w (F7)  the dissolution profile was found to be similar to the reference drug 
release profile. 
 
                         It was found that while increasing the concentration of Ethyl 
cellulose, drug release was decreased from the formulations. So by 
incorporating the pore forming agent like HPMC E5,the drug release was 
increased. F7 formulation containing 2.3% Ethyl cellulose N45 polymer was 
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found to be best of all the formulations showing drug release of 93.9% and 
matching with the drug release profile of the reference product. 
                         
                        The best formulation was repeated again for reproducibility, and 
all the quality control tests were done for conformation. The results were found 
to be super imposable with each other. 
 
                         Stability studies were conducted for optimized formulation (F7) 
at two different storage conditions 25ºc ± 2ºC /60%RH  ± 5% , 40ºC ± 2ºC 
/75%RH ± 5%for a period of 90 days. The formulation was found to be stable 
with respect to physical appearance, percentage moisture content, percentage 
drug content and percentage drug release. 
           
                        The optimized formula shall be utilized for the formulation 
development and also for other studies like bio-equivalence study, for successful 
launching of the product.            
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                                                       CONCLUSION 
 
                           The formulation containing 40mg of Methylphenidate 
Hydrochloride was prepared as extended release capsules.These techniques are 
particularly useful for patients who should not administer the drug in repeated 
intervals. 
 
                            The optimized formulation have consistent release profile to 
provide the drug release for longer duration of 10 hours. FTIR studies have 
shown that there was no considerable interactions between drug and 
excipients.The short term stability study also indicates no change in the physical 
characteristic of drug content. 
 
                            The comparision of dissolution profiles between the 
Methylphenidate Hydrochloride extended release capsules 40mg and the 
reference drug, showed no major changes in the dissolution profiles. Hence, it 
can be concluded that the Methylphenidate Hydrochloride extended release 
capsules were successfully developed and evaluated. 
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